Integrated agonistic antibodies

By designing specifically assembled antigen-binding molecules, the problem of difficult activation of IFNγ and IL-2 receptors in cancer immunotherapy has been solved, achieving selective activation and enhanced immune response, improving treatment efficacy and reducing side effects.

CN120882744APending Publication Date: 2025-10-31F HOFFMANN LA ROCHE & CO AG

Patent Information

Application Number
CN202480023431.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-04-03
Filing Date
2024-04-02
Publication Date
2025-10-31

AI Technical Summary

Technical Problem

In existing cancer immunotherapies, the use of cytokines such as IFNγ and IL-2 has problems such as difficulty in selectively activating receptors, poor stability, and significant side effects, resulting in poor treatment efficacy.

Method used

An antigen-binding molecule was designed, comprising a pair of complementary target-binding domains and a cytokine receptor-binding domain. By specifically assembling on the target antigen, it selectively activates IFNγ or IL-2 receptors, mimicking cytokine activity.

Benefits of technology

It achieves selective activation of IFNγ or IL-2 receptors at the tumor site, enhancing the immune response, improving treatment efficacy, and reducing side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The present application relates to antigen binding molecules comprising a pair of biparatomotic target binding domains, a pair of cytokine receptor binding domains and an Fc domain wherein the target binding domains concurrently bind to a target antigen and the cytokine receptor binding domains bind to a subunit of a cytokine receptor complex. Biparatopic assembly of the cytokine receptor binding domain in the presence of the target antigen allows for selective activation of cytokine receptors and efficient mimicking of cytokine activity in a targeted manner.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to an antigen-binding molecule comprising a pair of dual complementary target-binding domains, a pair of cytokine receptor-binding domains, and an Fc domain, wherein the target-binding domain simultaneously binds to a target antigen and the cytokine receptor-binding domain binds to a subunit of a cytokine receptor complex. The dual complementary assembly of the cytokine receptor-binding domains in the presence of the target antigen allows for selective activation of the cytokine receptor and effectively mimics cytokine activity in a targeted manner. Background Technology

[0002] In recent years, immunotherapy for cancer has seen explosive growth, and cancer immunotherapy is becoming a major strategy in the fight against the disease. For many cancer types, immune checkpoint modulators, including anti-PD-1, have become the standard of care. However, despite all the advances in cancer immunotherapy in recent years, a significant proportion of patients remain unresponsive to available immunotherapies due to intrinsic or adaptive resistance mechanisms. Patients with non-inflammatory immune conditions are more likely to be unresponsive to immunotherapy. Immune cell infiltration in tumors has been shown to be associated with a patient's ability to respond to immunotherapy. Developing new therapies aimed at increasing immune cell infiltration and enhancing immunogenicity is crucial for patients.

[0003] Parallel to the aforementioned developments, cytokines have garnered significant attention as potential cancer treatments. IFNγ (interferon-γ or IFN-γ) is a cytokine primarily produced by activated lymphocytes (such as CD4+). + and CD8 + T cells and natural killer cells (NK cells) produce IFNγ in response to immune or inflammatory stimuli. IFNγ is a homodimer, and its receptors (IFNγR1 and IFNγR2) are expressed in both hematopoietic and non-hematopoietic cells. IFNγR1 is stably expressed on the cell surface, while IFNγR2 is differentially expressed and regulates IFNγ. When IFNγ binds to its receptor, Janus kinases JAK1 and JAK2 are recruited and activated, phosphorylating and activating STAT1. Phosphorylated STAT1 translocates to the nucleus, binds to promoters, and regulates gene transcription under the control of IFNγ.

[0004] Unlike other cancer therapies currently on the market and under development, IFNγ acts on both tumor cells and immune cells, including T cells and dendritic cells. IFNγ has several benefits across different cell types, including 1) enhancing the expression of MHC-I molecules on the surface of both tumor cells and antigen-presenting cells, 2) recruiting immune cells to tumor sites by inducing the production of CXCL9, CXCL10, and CXCL11, and 3) increasing the ability to cross-present tumor antigens, subsequently enhancing anti-tumor immune responses. In addition to these effects, IFNγ also promotes the formation of a Th1 environment, monocyte differentiation, macrophage polarization, and angiogenesis. Because the IFNγ receptor is expressed on multiple cell types, the SINK effect may reduce its activity.

[0005] IFNγ can also exhibit undesirable side effects. Furthermore, issues with administration, bioavailability, and short half-life may arise. Therefore, novel molecules capable of selectively activating the IFNγ pathway at tumor sites are needed.

[0006] Targeting the interleukin-2 (IL-2) pathway has a long and fragmented history as a cancer immunotherapy strategy, demonstrating both significant clinical successes and complexities. IL-2 is a cytokine that activates lymphocytes and natural killer (NK) cells. Clinical efficacy is often masked by reports of IL-2-related toxicities associated with peripheral T cell activity and CD25-mediated complications.

[0007] Cytokines are potent immunomodulators that initiate signal transduction through receptor dimerization, but natural cytokines have some limitations as therapeutic agents. Low stability and difficulties in the production process are just some of them. Antibodies have long been known to induce signal transduction on cells, thus replacing natural ligands.

[0008] Recent literature provides increasing evidence that using both antibody-based and non-antibody-based protein scaffolds to bond heterodimeric cytokine receptors is a viable strategy for mimicking the activity of native cytokines. For example, Moraga et al. provided an early example of using dual antibodies as alternative ligands for the erythropoietin receptor (EpoR) (Moraga et al., Cell 160, 1196-1208 (2015)). Researchers at Teneobio used a mortar and pestle technique to combine pure heavy chain antibodies (VHH fused to the Fc domain) targeting different epitopes on the interleukin-2 receptor (IL-2Rβ and IL-2Rγ) into a bispecific effector IgG4 Fc (CH1 deletion). Although monospecific anti-IL-2Rβ or anti-IL-2Rγ in individual or mixed forms did not respond to human CD8 +STAT5 phosphorylation is induced on T cells, but bispecific anti-IL-2Rβγ antibodies show varying levels of agonist activity (Harris, KE, et al., Sci Rep 11(1): 10592 (2021)). Scientists at Synthekine employed a similar approach described by Teneobio, which describes the functional induction of signaling for both interleukin receptors (IL-2Rβ and IL-2Rγ) via single-domain antibodies (sdAbs; WO 2022 / 032040 A1), and was reviewed by Saxton and colleagues (Saxton, RA, et al., Nat Rev Drug Discov. 22, 21–37 (2022)). Researchers at Stanford University further expanded this approach, proposing a strategy to discover alternative agonists of cytokines using modular ligands such as VHH or scFv human interleukin-2 / 15, type I interferon, and interleukin-10 receptors. Interestingly, they also identified functional, non-natural assemblies, such as the IL-2Rβ / IL-10Rβ heterodimer (Yen, M., et al. Cell 185(8): 1414-1430 e1419 (2022)). The same authors also discussed a structure-based approach for decoupling the pro-inflammatory and anti-inflammatory functions of interleukin-10 (Saxton, RA, et al. Science 371(6535)(2021)). Two academic research groups from the Czech Republic and Israel jointly reported the discovery of antibody-based scaffolds mimicking the cytokine IFNλ. Combinatorial libraries derived from several established small protein scaffolds were used to identify variants capable of binding IFNλR1 or IL-10Rβ and inducing functional signaling (Kolarova, L., et al. FEBS J 289(9): 2672-2684 (2022)). Researchers at Medikine addressed the issue of reducing the size of the agonist module. They obtained molecules from a peptide library through a screening process designed to identify molecules that simultaneously bind to the Rα and γc subunits of the human IL-7 receptor. Those peptides with a molecular weight less than 5 kDa that fused to the IgG1-Fc domain exhibited biological properties similar to those of IL-7 in vitro and when administered to non-human primates (Dower, W., et al. Journal for Immuno Therapy of Cancer 8 (Suppl 3): A341-A342 (2020)).

[0009] Due to the pleiotropic nature of cytokines, new methods are needed to selectively activate cytokine receptors and effectively mimic cytokine activity. Summary of the Invention

[0010] This invention relates to novel antigen-binding molecules comprising cytokine receptor-binding domains, which, under the desired conditions of assembly at two complementary sites on a target antigen, are used as cytokine mimics for selectively activating receptor pathways.

[0011] The present invention relates to an antigen-binding molecule comprising i) a first target-binding domain, ii) a second target-binding domain, iii) a first cytokine receptor-binding domain, iv) a second cytokine receptor-binding domain, and v) an Fc domain, wherein the first target-binding domain is capable of binding to a first epitope on a target antigen and the second target-binding domain is capable of binding to a second epitope on a target antigen, wherein the first target-binding domain and the second target-binding domain do not compete for binding to tumor-associated antigens; and wherein the first cytokine receptor-binding domain is capable of binding to a first cytokine receptor subunit and the second cytokine receptor-binding domain is capable of binding to a second cytokine receptor subunit.

[0012] In one aspect, the first and second target-binding domains are antibody fragments, particularly Fv, Fab, scFv, scFab molecules, or single-domain antibodies. In one aspect, the first and second antigen-binding domains are Fab molecules. In one aspect, the first target-binding domain comprises a heavy chain variable domain (VH1), a light chain variable domain (VL1), a heavy chain constant domain (CH11), and a light chain constant domain (CL1), and the second target-binding domain comprises a heavy chain variable domain (VH2), a light chain variable domain (VL2), a heavy chain constant domain (CH12), and a light chain constant domain (CL2). In one aspect, the first and / or second antigen-binding domains are cross-Fab molecules. In one aspect, the first and / or second antigen-binding domains contain a charge mutation. In one aspect, the first target-binding domain is a cross-Fab and the second target-binding domain contains a charge mutation, or wherein the second target-binding domain is a cross-Fab and the first target-binding domain contains a charge mutation.

[0013] In one respect, the first target-binding domain and the second target-binding domain specifically bind to tumor-associated antigens or T-cell antigens.

[0014] In one respect, the first target-binding domain and the second target-binding domain specifically bind to FAP, PD-1, Her2, Her3, LAG-3, CEA, or EGFR. In one aspect, a) the first target-binding domain comprises VH1 of SEQ ID NO: 20 and VL1 of SEQ ID NO: 21, and the second target-binding domain comprises VH2 of SEQ ID NO: 22 and VL2 of SEQ ID NO: 23; or b) the first target-binding domain comprises VH1 of SEQ ID NO: 22 and VL1 of SEQ ID NO: 23, and the second target-binding domain comprises VH2 of SEQ ID NO: 20 and VL2 of SEQ ID NO: 21; or c) the first target-binding domain comprises VH1 of SEQ ID NO: 80 and VL1 of SEQ ID NO: 81, and the second target-binding domain comprises VH2 of SEQ ID NO: 82 and VL2 of SEQ ID NO: 83; or d) the first target-binding domain comprises VH1 of SEQ ID NO: 82 and VL2 of SEQ ID NO: 83. The first target-binding domain contains VH1 of SEQ ID NO: 80 and VL2 of SEQ ID NO: 81; the second target-binding domain contains VH1 of SEQ ID NO: 82 and VL1 of SEQ ID NO: 83, and the third target-binding domain contains VH2 of SEQ ID NO: 140 and VL2 of SEQ ID NO: 141; or the fourth target-binding domain contains VH1 of SEQ ID NO: 140 and VL1 of SEQ ID NO: 141, and the fifth target-binding domain contains VH2 of SEQ ID NO: 82 and VL2 of SEQ ID NO: 83.

[0015] In one aspect, both the first and second cytokine receptor subunits are subunits of the IFNγ receptor complex or the IL-2 receptor complex. In one aspect, a) the first cytokine receptor binding domain can bind IFNγR1 and the second cytokine receptor binding domain can bind IFNγR2, or b) the first cytokine receptor binding domain can bind IFNγR2 and the second cytokine receptor binding domain can bind IFNγR1; c) the first cytokine receptor binding domain can bind IL-2Rβ and the second cytokine receptor binding domain can bind IL-2Rγ, or d) the first cytokine receptor binding domain can bind IL-2Rγ and the second cytokine receptor binding domain can bind IL-2Rβ.

[0016] In one aspect, the first and second cytokine receptor-binding domains are antibody fragments, particularly Fv, Fab, scFv, scFab, single-domain antibodies, or VHH domains. In another aspect, the first and second cytokine receptor-binding domains are VHH domains. In one aspect, a) a first cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 5, and a second cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 9; or b) a first cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 9, and a second cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 5; or c) a first cytokine receptor-binding domain comprises a sequence selected from SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, and SEQ ID NO: 64, and a second cytokine receptor-binding domain comprises SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 5. The sequence of NO: 69, or d) the first cytokine receptor binding domain includes the sequences of SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68 and SEQ ID NO: 69, and the second cytokine receptor binding domain includes the sequences of SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62 and SEQ ID NO: 64.

[0017] In one aspect, the Fc domain comprises a first Fc domain subunit and a second Fc domain subunit. In one aspect, the Fc domain is an IgG Fc domain, particularly an IgG1 Fc domain. In one aspect, the Fc domain is a human Fc domain. 19. The antigen-binding molecule according to any one of the preceding claims, wherein in one aspect, the Fc domain comprises modifications that promote association between the first and second subunits of the Fc domain. In one aspect, the Fc domain comprises one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function.

[0018] In one aspect, a first cytokine receptor binding domain is fused at its C-terminus to the N-terminus of a first target-binding domain, specifically to the N-terminus of a first Fc domain subunit, and a second cytokine receptor binding domain is fused at its C-terminus to the N-terminus of a second target-binding domain, specifically to the N-terminus of a second Fc domain subunit, and a second target-binding domain is fused at its C-terminus to the N-terminus of a second Fc domain subunit, specifically to the C-terminus of a second target-binding domain, specifically to the C-terminus of a second target-binding domain, specifically to the N-terminus of a second target-binding domain subunit.

[0019] In one aspect, the antigen-binding molecule comprises a) a first polypeptide comprising, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VH1, and CH11; a second polypeptide comprising, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VH1, and CL1; a third polypeptide comprising, in sequence from the N-terminus to the C-terminus, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VH2, and CL2; or b) a first polypeptide comprising, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VL1, and CH11; a second polypeptide comprising, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VH1, and CL1; a third polypeptide comprising, in sequence from the N-terminus to the C-terminus, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from the N-terminus to the C-terminus, a second Fc domain subunit, VH1, and CL2; or b) a first polypeptide comprising, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VL1, and CH11; a second polypeptide comprising, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VH1, and CH11; a third polypeptide comprising, in sequence from the N-terminus to the C-terminus, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from the N-terminus to the C-terminus, a second Fc domain subunit, VH1, and CL2; or b) a first The following are examples of polypeptides: A first polypeptide comprising a second cytokine receptor-binding domain, VL1, and CL2, in sequence from N-terminus to C-terminus; or b) a first polypeptide comprising a first Fc domain subunit, VL1, and CL1, in sequence from N-terminus to C-terminus; a second polypeptide comprising a first cytokine receptor-binding domain, VH1, and CH11, in sequence from N-terminus to C-terminus; a third polypeptide comprising VL2, CH12, and a second Fc domain subunit, in sequence from N-terminus to C-terminus; and a fourth polypeptide comprising a second cytokine receptor-binding domain, VH2, and CL2, in sequence from N-terminus to C-terminus; or c) a first polypeptide comprising a first Fc domain subunit, VH1, and CL1, in sequence from N-terminus to C-terminus; a second polypeptide comprising a first cytokine receptor-binding domain, VL1, and CH11, in sequence from N-terminus to C-terminus; and a third polypeptide comprising VH2, CH12, and CH12, in sequence from N-terminus to C-terminus. and a second Fc domain subunit, and a fourth polypeptide comprising a second cytokine receptor-binding domain, VL2, and CL2 in sequence from the N-terminus to the C-terminus; or e) a first polypeptide comprising a first Fc domain subunit, VH1, and CH11 in sequence from the N-terminus to the C-terminus, a second polypeptide comprising a first cytokine receptor-binding domain, VL1, and CL1 in sequence from the N-terminus to the C-terminus, a third polypeptide comprising a second cytokine receptor-binding domain, VL2, CH12, and a second Fc domain subunit in sequence from the N-terminus to the C-terminus, and a fourth polypeptide comprising VH2 and CL2 in sequence from the N-terminus to the C-terminus;Or f) a first polypeptide comprising, in sequence from N-terminus to C-terminus, a first Fc domain subunit, VL1, and CH11; a second polypeptide comprising, in sequence from N-terminus to C-terminus, a first cytokine receptor-binding domain, VH1, and CL1; a third polypeptide comprising, in sequence from N-terminus to C-terminus, a second cytokine receptor-binding domain, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from N-terminus to C-terminus, VL2 and CL2; or g) a first polypeptide comprising, in sequence from N-terminus to C-terminus, a first Fc domain subunit, VL1, and CL1; a second polypeptide comprising, in sequence from N-terminus to C-terminus, a first cytokine receptor-binding domain, VH1, and CH1 ...L2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from N-terminus to C-terminus, a first Fc domain subunit, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from N- The following are possible sequences of peptides: a first peptide comprising, from N-terminus to C-terminus, VH2 and CL2; or a second peptide comprising, from N-terminus to C-terminus, a first Fc domain subunit, VH1 and CL1; a third peptide comprising, from N-terminus to C-terminus, a second Fc domain subunit, VH2, CH12 and a second Fc domain subunit; and a fourth peptide comprising, from N-terminus to C-terminus, VL2 and CL2; wherein VH1, VL1, CH11 and CL1 form the first target-binding domain, and VH2, VL2, CH12 and CL2 form the second target-binding domain.

[0020] In one aspect, the first target-binding domain and the second target-binding domain specifically bind to FAP, and the first cytokine receptor subunit and the second cytokine receptor subunit are subunits of the IFNγ receptor complex. In one aspect, the antigen-binding molecule comprises a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 50, a second polypeptide comprising the amino acid sequence of SEQ ID NO: 48, a third polypeptide comprising the amino acid sequence of SEQ ID NO: 51, and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 49; or b) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 99, a second polypeptide comprising the amino acid sequence of SEQ ID NO: 97, a third polypeptide comprising the amino acid sequence of SEQ ID NO: 100, and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 98; or c) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 103, a second polypeptide comprising the amino acid sequence of SEQ ID NO: 101, a third polypeptide comprising the amino acid sequence of SEQ ID NO: 104, and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 102; or d) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 107. The amino acid sequence of the first polypeptide, the second polypeptide comprising the amino acid sequence of SEQ ID NO: 105, the third polypeptide comprising the amino acid sequence of SEQ ID NO: 108, and the fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 106; or e) the first polypeptide comprising the amino acid sequence of SEQ ID NO: 99, the second polypeptide comprising the amino acid sequence of SEQ ID NO: 109, the third polypeptide comprising the amino acid sequence of SEQ ID NO: 100, and the fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 110; or f) the first polypeptide comprising the amino acid sequence of SEQ ID NO: 107, the second polypeptide comprising the amino acid sequence of SEQ ID NO: 111, the third polypeptide comprising the amino acid sequence of SEQ ID NO: 113, and the fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 112; or g) the first polypeptide comprising the amino acid sequence of SEQ ID NO: 99, the second polypeptide comprising the amino acid sequence of SEQ ID NO: 114 ...5, the fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 116, the fifth polypeptide comprising the amino acid sequence of SEQ ID NO: 117, the sixth polypeptide comprising the amino acid sequence of SEQ ID NO: 118, the seventh polypeptide comprising the amino acid sequence of SEQ ID NO: 119, the eighth polypeptide comprising the amino acid sequence of SEQ ID NO: 119, the ninth polypeptide comprising the amino acid sequence of SEQ ID NO: 119, the tenth polypeptide comprising the amino acid sequence of SEQ ID NO: 119, the eleventh polypeptide comprising the amino acid sequence of The amino acid sequence of the third polypeptide, which contains the amino acid sequence of SEQ ID NO: 100, and the amino acid sequence of the fourth polypeptide, which contains the amino acid sequence of SEQ ID NO: 115;Or h) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 107, a second polypeptide comprising the amino acid sequence of SEQ ID NO: 116, a third polypeptide comprising the amino acid sequence of SEQ ID NO: 108, and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 117.

[0021] In one aspect, the first target-binding domain and the second target-binding domain specifically bind to PD-1, and the first cytokine receptor subunit and the second cytokine receptor subunit are subunits of the IL-2 receptor complex.

[0022] In one aspect, the antigen-binding molecule comprises: a first polypeptide comprising the amino acid sequence of SEQ ID NO: 123; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 122; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 124; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 125. Attached Figure Description

[0023] Figure 1. Schematic representation of antigens used for llama immunization, phage display, and screening to isolate human IFNγR1, IFNγR2, IL-2Rβ, and IL-2Rγ specific single-domain antibodies. For llama immunization, heterodimers are generated consisting of the extracellular domain (ECD) of human IFNγR1 fused with biotinylated Fc spur and the ECD of human IFNγR2 fused with Fc spur (A), and heterodimers consisting of the ECD of human IL-2Rβ fused with biotinylated Fc spur and the ECD of human IL-2Rγ fused with Fc spur (D). For phage display, monovalent human IFNγR1 fused with biotinylated Fc (B), monovalent human IFNγR2 fused with biotinylated Fc (C), monovalent human IL-2Rβ fused with biotinylated Fc (E), and monovalent human IL-2Rγ fused with both biotinylated Fc (F) and soluble Fc (G) were generated.

[0024] Figure 2. Workflow for demonstrating the enrichment of single-domain antibodies with binding specificity to human cytokine receptor subunits via phage.

[0025] Figure 3. Specificity of single-domain antibodies screened by ELISA. The binding of a set of random soluble VHH domains selected for human IFNγR1 specificity after three rounds of phage display to immobilized human IFNγR1-Fc and immobilized human Fc was tested (A). The antigen specificity of VHH domains with human IFNγR2 specificity after three rounds of phage display was also tested by ELISA (B). The binding of VHH domains selected for human IL-2Rβ specificity after three rounds of phage display to immobilized human IL-2Rβ-Fc and immobilized human Fc was tested (C). The antigen specificity of VHH domains with human IL-2Rγ specificity after three rounds of phage display was also tested by ELISA (D). The absorbance at 450 nm, indicating the binding reaction to each target, is shown as a stacked bar graph.

[0026] Figure 4. Format conversion of single-domain antibody fragments. Third-round VHH library variants with IFNγR1 or IL-2Rβ specificity were fused with Fc clathrin and cloned into mammalian cell expression vectors using the Gibson cloning method (A). Third-round VHH library variants with IFNγR2 or IL-2Rγ specificity were fused with Fc clathrin using the same method (B).

[0027] Figure 5. Bispecific heavy chain antibodies containing IFNγR1-IFNγR2 or IL-2Rβ-IL-2Rγ VHH domain pairs. VHH domains specific for IFNγR1 or IL-2Rβ were fused to the Fc moiety, and VHH domains targeting IFNγR2 or IL-2Rγ were fused to the Fc moiety. The VHH moieties were fused to the Fc chain using a flexible 5 (G4S) linker. Bispecific heavy chain antibodies were generated via assembly of the Fc moiety. Effector functions of the Fc were silenced by incorporating a P329G LALA mutation into the CH2 domain.

[0028] Figure 6. Functional screening of bispecific heavy chain antibodies containing IFNγR1-IFNγR2 or IL-2Rβ-IL-2Rγ VHH domain pairs. HEK-blue IFNγ cells were incubated with IFNγ agonist bispecific heavy chain antibodies containing IFNγR1 and IFNγR2 VHH domain pairs generated using a 5x5 bispecific matrix (A). HEK-blue IL-2 receptor cells were incubated with IL-2 agonist bispecific heavy chain antibodies containing IL-2Rβ and IL-2Rγ VHH pairs generated using a 5x5 bispecific matrix (B). IFNγR and IL-2R activities were quantified by absorbance at 650 nm, and the fold-over response / background for each treatment is shown.

[0029] Figure 7. Characterization of dose-dependent responses to IFNγ agonist heavy chain antibodies. The dose-dependent IFNγR activity of previously identified IFNγR agonists (Figure 6A, Table 1) in HEK blue IFNγ cells was screened and characterized by absorbance at 650 nm. Responses to different IFNγ agonist heavy chain antibodies were grouped according to the anti-IFNγR1 VHH clone, i.e., the anti-IFNγR2 VHH clone was variable in each figure, while the anti-IFNγR1 VHH clone remained constant: IFNγR1_1 clone (A), IFNγR1_2 clone (B), IFNγR1_3 clone (C), and IFNγR1_5 clone (D). Responses were compared to recombinant human IFNγ (black dashed line) and FAP-IFNγ (P1AF3574; light gray dashed line).

[0030] Figure 8. Comparison of EC50 values ​​for IFNγ agonist heavy chain antibodies. EC50 values ​​were derived from the HEK blue assay using GraphPadPrism software (Figure 7). Values ​​are plotted as nanomolar concentrations, with prominent recombinant human IFNγ as a reference (dashed line).

[0031] Figure 9. Characterization of dose-dependent responses to IL-2R agonist heavy chain antibodies. Previously identified IL-2R agonists (Figure 6B, Table 2) were screened for dose-dependent IL-2R agonists in HEK blue IL-2 cells. Anti-PD1-IL2v (P1AE4422) was used as a reference molecule, and each molecule was incubated with reporter cells at the following concentrations: 20 nM, 0.8 nM, and 0.032 nM, shown from left to right. IL-2R activity was quantified by absorbance at 650 nm; the average from three technical replicates is shown, with error bars representing standard deviations.

[0032] Figure 10. MHC-I and PD-L1 expression on tumor cells 72 h after IFNγ agonist treatment. Previously identified IFNγR agonists (P1AH1877-P1AH1890) and reference molecules (recombinant human IFNγ and FAP-IFNγ) were incubated with tumor cells at the following treatment concentrations: 100, 10, 1, and 0.1 nM, shown from left to right for each treatment. Measurements were subtracted from blank and normalized to the highest concentration (100 nM) of recombinant human IFNγ response. The responses of MHC-I expression (A), PD-L1 expression (B), MHC-I expression (C), PD-L1 expression (D), MHC-I expression (E), and PD-L1 expression (F) on MKN45 cells, Bxpc3 cells, and CorL105 cells are depicted.

[0033] Figure 11. Concept of a split dual-targeting IFNγR agonist. FAP-dependent bicomponent assembly of a split IFNγ mimic (A). Note that, for illustrative simplicity, only one monomer of the FAP dimer is shown in the illustration. The VHH domains, which are specific to IFNγR1 and IFNγR2, are fused to the N-terminus of two different anti-FAP binding domains via VH or VL fusion sites, resulting in eight configurations within the substitution space: IFNγR1-VHH fused to the VH of FAP binder 1 (B), IFNγR2-VHH fused to the VH of FAP binder 2 (C), IFNγR1-VHH fused to the VL of FAP binder 1 (D), IFNγR2-VHH fused to the VL of FAP binder 2 (E), IFNγR2-VHH fused to the VH of FAP binder 1 (F), IFNγR1-VHH fused to the VH of FAP binder 2 (G), IFNγR2-VHH fused to the VL of FAP binder 1 (H), and IFNγR2-VHH fused to the VL of FAP binder 1 (H). VL-fused IFNγR1-VHH (I) of binder 2. All molecules have the same Fc properties as described in Figure 5.

[0034] Figure 12. Evaluation of IFNγR activity mediated by FAP-dependent cleaving IFNγR agonists. Eight cleaving IFNγ mimics (Figure 11B-I) were paired in a double complementary assembly and tested for IFNγR agonists characterized by MHC-I and PD-L1 upregulation. Non-targeted, non-specific MHC-I (A, B) and PD-L1 upregulation (C, D) in FAP-negative A549 cells were tested using cleaving IFNγ mimics. A549 FAP-positive cells were co-cultured with differentially labeled A549 FAP-negative cells to evaluate the FAP-dependent activity of IFNγ mimics in cis and trans: cis-upregulation of MHC-I (E and F), cis-upregulation of PD-L1 (G and H), trans-upregulation of MHC-I (I and J), and trans-upregulation of PD-L1 (K and L). Recombinant IFNγ and IFNγ agonist heavy chain antibody P1AH1884 (shown in Figure 5) were used as references. Median fluorescence intensity (MFI) of MHC-I and PD-L1 expression levels was analyzed in FlowJo; the mean from two technical replicates is shown, with error bars representing standard deviation.

[0035] Figure 13. Additional configurations of split dual-targeting IFNγR agonists. By fusing the VHH domain, which is specific for both IFNγR1 and IFNγR2, away from the anti-FAP binder via fusion with the N-terminus of the opposing Fc chain, four configurations are obtained: IFNγR1 and FAP binder 1 (A), IFNγR2 and FAP binder 2 (B), IFNγR2 and FAP binder 1 (C), and IFNγR1 and FAP binder 2 (D). Alternatively, by fusing the VHH domains with IFNγR1 and IFNγR2 specificity away from the anti-FAP binder via fusion with the C-terminus of the same Fc chain, four configurations are obtained: IFNγR1 and FAP binder 1 (E), IFNγR2 and FAP binder 2 (F), IFNγR2 and FAP binder 1 (G), and IFNγR1 and FAP binder 2 (H). The anti-FAP binders in Figures 13E-H contain cross-Fab VH / VL engineering (binding agent 1) and CH1-CL charge (binding agent 2) to subsequently allow for additional pairing. All molecules possess the same Fc properties as described in Figure 5.

[0036] Figure 14. Evaluation of IFNγR activity mediated by additional FAP-dependent cleavage IFNγR agonists. Four combinations of the molecules depicted in Figure 13 and a reference molecule were tested for IFNγR agonists characterized by MHC-I and PD-L1 upregulation. FAP-independent MHC-I upregulation (A) and PD-L1 upregulation (B) of cleavage IFNγ mimics in A549 cells lacking FAP expression were tested. A549 FAP-positive cells were co-cultured with differentially labeled A549 FAP-negative cells to evaluate the FAP-dependent activity of IFNγ mimics by MHC-I cis upregulation (C), PD-L1 cis upregulation (D), MHC-I trans upregulation (E), and PD-L1 trans upregulation (F). Recombinant IFNγ and IFNγ agonist heavy chain antibody (P1AH1884) were used as reference molecules. Median fluorescence intensity (MFI) of MHC-I and PD-L1 expression levels was analyzed in FlowJo; the mean from two technical replicates is shown, with error bars representing standard deviation.

[0037] Figure 15. Concept of a split dual-targeting IL-2 agonist. PD-1-dependent bicomponent assembly of a split IL-2 mimic (A). A VHH domain with IL-2Rβ and IL-2Rγ specificity is fused to the N-terminus of two different anti-PD-1 binding domains via a VH or VL fusion site: IL-2Rβ-VHH fused to the VH of PD-1 binder 1 (B), IL-2Rγ-VHH fused to the VL of PD-1 binder 2 (C), IL-2Rβ-VHH fused to the VL of PD-1 binder 1 (D), and IL-2Rγ-VHH fused to the VH of PD-1 binder 2 (E). An IL-2 agonist heavy chain antibody (F) and PD-1-IL2v (G) are used as reference molecules. All molecules have the same Fc properties as described in Figure 5.

[0038] Figure 16. Phosphorylation of STAT5 on CD4 T cells after incubation with IL-2R agonists for 15 min and 60 min. (PD-1 expression) + Activated T cells (subgroup) and those treated with anti-PD-1 antibody (PD-1) - Pre-blocked activated T cells (subgroups) were differentially labeled and treated with two combinations of split dual-targeting IL-2 mimics: P1AH6850 + P1AH6813 (AD) and P1AH6814 + P1AI1593 (EH). IL-2 mimic heavy chain antibody (P1AH1177) and PD1-IL2v (P1AE4422) were used as reference molecules. STAT5-P was measured by FACS. + Cellular MFI and frequency, and show PD-1 + Subgroup (solid line) and PD-1 - The reaction of the subgroup (dashed line).

[0039] Figure 17. Concept of a PD-1-targeting IL-2R agonist with alternative anti-PD-1 Fab binders. The VHH domain, which is specific for both IL-2Rβ and IL-2Rγ, is fused to the N-terminus of two different anti-PD-1 binding domains via the VH or VL fusion site, resulting in eight individual configurations (P1AK2599; P1AK2798; P1AK2799; P1AK2802; P1AK2803; P1AK2806; P1AK2809; P1AK2810). These configurations can be paired to produce the eight functional assemblies depicted: P1AK2802 + P1AK2599 (A), P1AK2809 + P1AK2799 (B), P1AK2803 + P1AK2806 (C), P1AK2810 + P1AK2798 (D), P1AK2809 + P1AK2599 (E), P1AK2802 + P1AK2799. (F), P1AK2810 + P1AK2806 (G) and P1AK2803 + P1AK2798 (H).

[0040] Figure 18. Functional activity of PD-1-targeting IL-2R agonists with alternative anti-PD-1 Fab binders. The test compounds were incubated with HEK blue IL-2 wt cells (A) or HEK blue IL-2 human PD-1 cells (B) at 37°C and 5% CO2 for 21 h. PD1-IL2v (P1AE4422) and Fc-VHH (P1AH1177) were used as references. An unbound DP47 antibody (P1AD3966) was used as a negative control. IL-2R signaling was measured via absorbance at 650 nm using QUANTI blue reagent. The mean absorbance values ​​for each tested molecular concentration, repeated three times, are shown in the + / - SEM.

[0041] Figure 19. Schematic representation of the 'integrated' format design. A pair of IFNγ mimic molecules (P1AI0831 and P1AI0066) exhibiting both potent cis and trans activities were formatted as a single molecule to test FAP-specific activity. One of the anti-FAP binding domains was transplanted to the C-terminus of Fc to achieve sufficient molecular spacing between the IFNγ mimic VHH pairs, thereby avoiding FAP-independent IFNγR activation. Cross-Fab VH / VL engineering and CH1-CL charge were combined to produce a four-specificity format (P1AI5012) in which Fc exhibits the same properties described in Figure 5.

[0042] Figure 20. Assessment of FAP-specific IFNγR activity mediated by the 'integrated' IFNγ mimic. Non-targeted, non-specific MHC-I upregulation (A) and PD-L1 upregulation (B) of the 'integrated' IFNγ mimic (P1AI5012) in FAP-negative A549 cells were tested. A549 FAP-positive cells were co-cultured with differentially labeled A549 FAP-negative cells to assess FAP-dependent cis-upregulation of MHC-I (C), cis-upregulation of PD-L1 (D), trans-upregulation of MHC-I (E), and trans-upregulation of PD-L1 (F) of the IFNγ mimic. Recombinant IFNγ and the IFNγ agonist heavy chain antibody P1AH1884 were used as references. The median fluorescence intensity (MFI) of MHC-I and PD-L1 expression was analyzed in FlowJo; the mean from two technical replicates is shown, with error bars representing standard deviation.

[0043] Figure 21. Schematic representation of additional formats of the 'integrated' molecule. Variants of the integrated molecule P1AI5012 (A) differ in their agonist VHH pairs, the position of VHH (either on the VH or VL of the Fab domain), and the position of the FAP binder. P1AJ0690 (B), P1AJ0672 (C), P1AJ0700 (D), P1AJ0685 (E), P1AJ0744 (F), P1AJ0735 (G), and P1AJ0747 (H).

[0044] Figure 22. MHC-I expression on tumor cells 72 h after IFNγ agonist treatment. Previously identified IFNγ agonists (P1AI5012, P1AJ0690, P1AJ0672, P1AJ0685, P1AJ0700, P1AJ0747, P1AJ0744, and P1AJ0735) and a reference molecule (recombinant human IFNγ) were incubated with tumor cells. A549 FAP-positive cells were co-cultured with differentially labeled A549 FAP-negative cells to assess the FAP-dependent activity of IFNγ mimics in cis and trans: cis-upregulation of MHC-I (A) and trans-upregulation of MHC-I (B). Median fluorescence intensity (MFI) of MHC-I expression levels was analyzed in FlowJo; the mean from two technical replicates is shown, with error bars representing standard deviation.

[0045] Figure 23. Schematic representation of the 'integrated' format design. Bicomponent splitting IL-2 mimic molecules (P1AI1593 and P1AH6814) with potent PD1-mediated cis-activity were formatted as a single-molecule (P1AI5057) to test PD1-restricted activity. A set of anti-PD1 and anti-IL2Rβ binding domains were transplanted to the C-terminus of the Fc to achieve sufficient molecular spacing between the IL-2 mimic VHH pairs, thereby reducing PD1-independent IL-2R activation. To generate the four-specificity format, a cross-Fab VH / VL engineering and CH1-CL charge were incorporated into the Fab domain, and a club-and-mortar mutation was present in the Fc. The effector function of the Fc was silenced by incorporating a P329G LALA mutation into the CH2 domain.

[0046] Figure 24. Functional activity of the integrated PD-1-targeting IL2R agonist. The test compounds were incubated with HEK blue IL-2 wt or HEK blue IL-2 in human PD-1 cells at 37 °C and 5% CO2 for 20 h. PD1-IL2v (P1AE4422) and Fc-VHH (P1AH1177) were used as references. An unbound DP47 antibody (P1AD3966) was used as a negative control. IL2R signaling was measured via absorbance at 650 nm using QUANTI blue reagent. The mean absorbance values ​​(+ / -) for each tested molecular concentration are shown in the SEM, repeated three times.

[0047] Figure 25: Concept of a PD-1-targeting IL-2R agonist assembled with a single complementary site onto PD-1. A VHH domain with IL-2Rβ and IL-2Rγ specificity is fused to the N-terminus of two anti-PD1 binding domains with the same complementary site via a VH or VL fusion site. P1AM4293 (A) contains two anti-PD1 binding domains with the complementary site FV000363 (PD1 binder 1; 0376 binder), and P1AM4294 (B) contains two anti-PD1 binding domains with the complementary site FV003451 (PD1 binder 2; 1040 binder).

[0048] Figure 26: Functional activity of IL-2R agonists targeting PD-1 with single and double complementary sites. Test compounds were incubated with HEK blue IL-2 wt or HEK blue IL-2 in human PD-1 cells at 37 °C and 5% CO2 for 18 h. Fc-VHH (P1AH1177) was used as a reference. An unbound DP47 antibody (P1AD3966) was used as a negative control. IL-2R signaling was measured via absorbance at 650 nm using QUANTI blue reagent. The fold change in IL-2R signaling on background + / - SEM is shown for each tested molecular concentration, repeated twice. Detailed Implementation

[0049] definition

[0050] Unless otherwise defined herein, scientific and technical terms related to this invention shall have the meanings commonly understood by one of ordinary skill in the art. Furthermore, unless the context requires otherwise, singular terms shall include plural terms, and plural terms shall include singular terms. The methods and techniques of this disclosure are generally performed according to conventional methods known in the art. Typically, terms and techniques related to biochemistry, enzymology, molecular and cell biology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization as described herein are well-known and commonly used in the art.

[0051] Unless the context clearly indicates otherwise, the terms “a,” “an,” or “the” generally include a plural reference.

[0052] As used herein, the terms “first,” “second,” or “third” for binding molecules, epitopes, peptides, etc., are used for ease of distinction when there is more than one part of each type. Unless explicitly stated otherwise, the use of these terms is not intended to assign a particular order or orientation to the parts.

[0053] As used in this article, the term "antigen-binding molecule" refers to a polypeptide molecule (composed of one or more polypeptide chains) capable of binding antigens. Binding molecules may be derived from antibodies and typically contain an antigen-binding domain.

[0054] The term “antibody” is used in the broadest sense and includes a variety of antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), heavy chain antibodies, antibody fragments, and antigen-binding molecules, as long as they exhibit the desired antigen-binding activity.

[0055] The terms “heavy chain antibody”, “pure heavy chain antibody”, and “HCAb” used in this article refer to antibodies that do not contain light chains.

[0056] The terms “full-length antibody,” “intact antibody,” and “whole antibody” are used interchangeably in this document to refer to antibodies that have a structure substantially similar to that of natural antibodies.

[0057] An "antibody fragment" is a molecule other than a complete antibody that contains a portion of the complete antibody and binds to the antigen bound by the complete antibody. Examples of antibody fragments include, but are not limited to, Fv, Fab, cross-Fab, Fab', Fab'-SH, F(ab')2, bispecific antibodies, linear antibodies, single-chain antibody molecules (e.g., scFv and scFab), single-domain antibodies, and multispecific antibodies formed from antibody fragments. For a review of some antibody fragments, see Hollinger and Hudson, Nature Biotechnology 23:1126-1136 (2005).

[0058] "Single-domain antibody" refers to an antibody fragment composed of a single monomeric antibody variable domain such as VHH, nanobodies, shark-derived VNAR, autonomous VH domain, or autonomous VL domain. Single-domain antibodies provide antigen-binding sites that specifically bind to epitopes; that is, the antigen-binding site is formed solely by the single-domain antibody.

[0059] "VHH," "VHH domain," or "nanobody" refers to a single-domain antibody derived from a heavy-chain antibody of camelids (such as camels, dromedaries, llamas, and alpacas) with a variable domain (see Nguyen VK et al., 2000, The EMBO Journal, 19, 921-930; Muyldermans S., 2001, J Biotechnol., 74, 277-302 and for review Vanlandschoot P. et al., 2011, Antiviral Research 92, 389-407). The antigen-binding site of a VHH does not contain a light-chain variable domain. The VHH domain can be humanized.

[0060] As used herein, "antigen-binding domain" refers to a domain that specifically binds to a target antigen. This term specifically refers to the antigen-binding domain of an antibody, i.e., the portion containing part or all of the region that binds to and is complementary to the antigen. Therefore, in a particular respect, the antigen-binding domain herein is the antigen-binding domain of an antibody. Such antigen-binding domains can be provided by antibody fragments, such as Fab molecules, single-chain antibody molecules, or single-domain antibodies, such as VHH domains.

[0061] The term "variable region" or "variable domain" refers to a domain of the antibody heavy or light chain involved in antibody-antigen binding. This term includes the VHH domain. The variable domains (VH and VL, respectively) of the heavy and light chains of natural antibodies typically have similar structures, with each domain containing four conserved frame regions (FRs) and complementarity-determining regions (CDRs). See, for example, Kindt et al., Kuby Immunology, 6th ed., WH Freeman & Co., p. 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies binding to a specific antigen can be isolated using either the VH or VL domain from the antibody binding that antigen to screen for libraries with complementary VL or VH domains. See, for example, Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991). As used in conjunction with variable region sequences in this article, "Kabat numbering" refers to the numbering system proposed by Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991).

[0062] As used herein, the amino acid positions of all constant regions and constant domains of the heavy and light chains are numbered according to the Kabat numbering system described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991), and are referred to herein as “according to Kabat numbering” or “Kabat numbering”.

[0063] Specifically, the Kabat numbering system (see Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991), pp. 647–660) is used for the light chain constant domain CL of the κ and λ isoforms, and the Kabat EU index numbering system (see pp. 661–723) is used for the heavy chain constant domains (CH1, hinge, CH2, and CH3), which is further explained in this paper by referring to it as “according to Kabat EU index numbering” or “Kabat EU index numbering” in this context.

[0064] As used herein, the term "binding site" or "antigen binding site" refers to a site, i.e., one or more amino acid residues, that provides a binding molecule for interaction with an antigen. For example, the antigen binding site of an antigen-binding domain contains amino acid residues from a complementarity determining region (CDR). The antigen binding site can be provided, for example, by one or more variable domains (also called variable regions). In single-domain antibodies, the antigen binding site is provided by a single variable domain. In Fab fragments, the antigen binding site is provided by VH and VL domains.

[0065] As used herein, the term "hypervariant region" or "HVR" refers to the individual regions within an antigen-binding domain that are sequence-hypervariant and determine antigen-binding specificity, such as "complementarity-determining regions" ("CDRs"). Typically, a variable domain contains three CDRs. Therefore, an antibody containing both VH and VL contains six CDRs; three in VH (HCDR1, HCDR2, HCDR3) and three in VL (LCDR1, LCDR2, LCDR3). Exemplary CDRs in this document include:

[0066] (a) Hypervariable rings present at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987));

[0067] (b) CDRs located at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991)); and

[0068] (c) Antigen contact sites located at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2) and 93-101 (H3) (MacCallum et al., J. Mol. Biol. 262:732-745 (1996)).

[0069] Unless otherwise stated, the CDR is determined according to the method described by Kabat et al. (ibid.). Those skilled in the art will understand that the CDR name can also be determined according to the methods described by Chothia (ibid.), McCallum (ibid.), or any other scientifically accepted naming system.

[0070] “Frame” or “FR” refers to the variable domain residues other than the complementarity-determining region (CDR). The FR of a variable domain typically consists of four FR domains: FR1, FR2, FR3, and FR4. Therefore, the HVR and FR sequences typically appear in the VH and VHH (or VL) domains in the following order: FR1-HCDR1 (LCDR1)-FR2-HCDR2 (LCDR2)-FR3-HCDR3 (LCDR3)-FR4. Unless otherwise specified, CDR residues and other residues (e.g., FR residues) in the variable domain are numbered in this document according to Kabat et al., ibid.

[0071] The term "immunoglobulin molecule" in this article refers to a protein with the structure of naturally occurring antibodies. For example, IgG immunoglobulins are heterotetrameric glycoproteins of approximately 150,000 Daltons, composed of two light chains and two heavy chains linked by disulfide bonds. Each heavy chain has a variable domain (VH) (also called a variable heavy chain domain or heavy chain variable region) from the N-terminus to the C-terminus, followed by three constant domains (CH1, CH2, and CH3) (also called heavy chain constant regions). Similarly, each light chain has a variable domain (VL) (also called a variable light chain domain or light chain variable region) from the N-terminus to the C-terminus, followed by a constant light chain (CL) domain (also called a light chain constant region). The heavy chains of immunoglobulins can be classified into one of five types, referred to as α (IgA), δ (IgD), ε (IgE), γ (IgG), or µ (IgM), some of which can be further subdivided into subtypes such as γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1), and α2 (IgA2). The light chains of immunoglobulins can be assigned to one of two types based on the amino acid sequence of their constant domains: called kappa (κ) and lambda (λ). Immunoglobulins essentially consist of two Fab molecules linked by an immunoglobulin hinge region and an Fc domain.

[0072] The "class" of an antibody or immunoglobulin refers to the type of constant domain or region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and some of them can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The constant domains of the heavy chain corresponding to different classes of immunoglobulins are respectively called α, δ, ε, γ, and μ.

[0073] A “Fab molecule” or “Fab” or “Fab fragment” refers to a protein composed of the VH and CH1 domains of the heavy chain (“Fab heavy chain”) and the VL and CL domains of the light chain (“Fab light chain”) of an immunoglobulin.

[0074] A "cross-Fab molecule," or "exchangeable Fab molecule," refers to a Fab molecule in which the variable or constant regions of the heavy and light chains are exchanged. Cross-Fab engineering achieves two different chain compositions for cross-Fab molecules. In one aspect, the variable regions of the Fab heavy and light chains are exchanged; that is, the cross-Fab molecule comprises a peptide chain consisting of a light chain variable region (VL) and a heavy chain constant region (CH1) (where CH1 can fuse with an Fc domain), and a peptide chain consisting of a heavy chain variable region (VH) and a light chain constant region (CL). In the other aspect, when the constant regions of the Fab heavy and light chains are exchanged, the cross-Fab molecule comprises a peptide chain consisting of a heavy chain variable region (VH) and a light chain constant region (CL) (where CL can fuse with an Fc domain), and a peptide chain consisting of a light chain variable region (VL) and a heavy chain constant region (CH1).

[0075] The term "conventional Fab molecule" refers to a Fab molecule consisting of a Fab heavy chain containing VH and CH1 domains and a Fab light chain containing VL and CL domains.

[0076] The term "multispecific" means that a binding molecule (e.g., an antibody) can specifically bind to at least two different antigens. A multispecific binding molecule (e.g., an antibody) can be, for example, a bispecific binding molecule. Typically, a bispecific binding molecule contains two antigen-binding sites, each of which is specific for a different antigen. In some respects, multispecific (e.g., bispecific) binding molecules can bind to two antigens simultaneously, particularly two antigens expressed on cells in the same cell, adjacent cells, or cells in the same tissue.

[0077] As used herein, the term "valence" indicates the presence of a specified number of antigen-binding sites in the binding molecule. Therefore, the term "monovalently bound antigen" indicates the presence of one (and no more than one) antigen-binding site in the binding molecule that is specific to the antigen.

[0078] As used herein, the term "antigen" refers to a molecule, such as a protein, to which an antigen-binding molecule binds. Useful antigens can be found, for example, on the surface of tumor cells, on the surface of tumor stromal cells, on the surface of virus-infected cells, on the surface of other diseased cells, on the surface of immune cells, in serum, and / or in the extracellular matrix (ECM). In one particular context, antigens are human proteins.

[0079] As used herein, the term "epitope" refers to a site on an antigen to which an antigen-binding site binds. Epitopes can be formed from continuous amino acid fragments or conformations composed of different regions of non-continuous amino acids. Epitopes typically include chemically active surface groups of the antigen, such as amino acids, glycan side chains, phosphoryl groups, or sulfonyl groups, and may have specific three-dimensional structural features and / or specific charge features. Two different antigen-binding domains capable of binding the same antigen may bind different epitopes of said antigen. If two antigen-binding domains can bind the antigen simultaneously, these different antigen-binding domains are said not to compete for binding. In this case, the two different antigen-binding domains are non-competitive. Alternatively, antigen-binding domains may compete for binding, i.e., exhibit competitive binding. This may be due to partially overlapping epitopes or due to steric hindrance preventing the simultaneous binding of two antigen-binding domains. Assays that determine whether an antigen-binding domain exhibits non-competitive or competitive binding are well known in the art, such as competitive binding assays using ELISA, RIA, surface plasmon resonance, flow cytometry, or any other quantitative or qualitative antibody binding assay available in the art.

[0080] As used in this article, “target antigen” refers to an antigen present on the surface of target cells, such as antigens on cells in a tumor (e.g., cancer cells or cells in the tumor stroma) or antigens on T cells.

[0081] As used in this article, "tumor-associated antigen" refers to any antigen present on the surface of cells in a tumor (such as cancer cells or cells in the tumor stroma). Specific tumor-associated antigens include CEA, FAP, Her2, Her3, or EGFR.

[0082] The term "fibroblast activating protein (FAP)," also known as prolyl endopeptidase FAP or Seprase (EC 3.4.21), refers to any naturally occurring FAP from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats), unless otherwise specified. FAP is expressed on cancer-associated fibroblasts (CAFs) in the tumor stroma. The term includes "full-length" unprocessed FAP, as well as any form of FAP produced through cellular processing. The term also covers naturally occurring variants of FAP, such as splice variants or allelic variants. In one embodiment, the antigen-binding molecule of the present invention is capable of specifically binding to human, mouse, and / or cynomolgus monkey FAP. The amino acid sequence of human FAP is shown in UniProt (www.uniprot.org) accession number Q12884 (version 149) or NCBI (www.ncbi.nlm.nih.gov / ) RefSeqNP_004451.2. The extracellular domain (ECD) of human FAP extends from amino acid position 26 to position 760. The amino acid sequence of mouse FAP is shown in UniProt accession number P97321 (version 126) or NCBI RefSeqNP_032012.1. The extracellular domain (ECD) of mouse FAP extends from amino acid position 26 to amino acid position 761. Preferably, the anti-FAP binding molecule binds to the extracellular domain of FAP. Exemplary anti-FAP binding molecules are described in international patent applications WO 2012 / 020006 A2 and WO 2020 / 070041 A1.

[0083] The term “carcinoembryonic antigen (CEA)”, also known as carcinoembryonic antigen-associated cell adhesion molecule 5 (CEACAM5), refers to any naturally occurring CEA from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats), unless otherwise specified. The amino acid sequence of human CEA is shown in UniProt accession number P06731 (version 151). CEA has long been identified as a tumor-associated antigen (Gold and Freedman, J Exp Med., 121:439-462, 1965; Berinstein NL, J Clin Oncol., 20:2197-2207, 2002). Initially classified as a protein expressed only in fetal tissues, CEA has now been identified in a variety of normal adult tissues. These tissues are primarily epithelial, including cells from the gastrointestinal tract, respiratory tract, and urogenital tract, as well as cells from the colon, cervix, sweat glands, and prostate (Nap et al., Tumour Biol., 9(2-3):145-53, 1988; Nap et al., Cancer Res., 52(8):2329-23339, 1992). Epithelial-derived tumors and their metastases all contain CEA as a tumor-associated antigen. The presence of CEA itself does not indicate conversion to cancer cells, but the distribution of CEA is indicative. In normal tissues, CEA is usually expressed on the apical surface of cells (Hammarström S., Semin Cancer Biol. 9(2):67-81 (1999)), preventing it from being absorbed by antibodies in the bloodstream. Compared to normal tissues, CEA tends to be expressed across the entire surface of cancer cells (Hammarström S., Semin Cancer Biol. 9(2):67-81 (1999)). This change in expression pattern makes CEA more susceptible to binding to antibodies in cancer cells. Furthermore, CEA expression is increased in cancer cells. In addition, increased CEA expression promotes increased cell-cell adhesion, which may lead to metastasis (Marshall J., Semin Oncol., 30(a Suppl. 8):30-6, 2003). CEA expression is generally very high in various tumor entities.Based on published data, our own analysis of tissue samples confirmed the high prevalence of CEA, with an incidence of approximately 95% in colorectal cancer (CRC), 90% in pancreatic cancer, 80% in gastric cancer, 60% in non-small cell lung cancer (NSCLC, co-expressed with HER3), and 40% in breast cancer; and low expression levels were found in small cell lung cancer and glioblastoma.

[0084] Unless otherwise specified, “HER2” (also known as erbB-2 or CD340) refers to any native HER2 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). The term covers “full-length” unprocessed HER2, as well as any form of HER2 produced through cellular processing. The term also covers naturally occurring variants of HER2, such as splice variants or allelic variants. In one respect, HER2 is human HER2. The amino acid sequence of human HER2 is shown in UniProt (www.uniprot.org) entry number Q9UK79 (95th edition).

[0085] “Epidermal growth factor receptor (EGFR),” also known as proto-oncogene c-ErbB-1 or receptor tyrosine protein kinase erbB-1, refers to any naturally occurring EGFR from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats), unless otherwise specified. The amino acid sequence of human EGFR is shown in UniProt accession number P00533.

[0086] As used in this article, “T cell antigen” refers to any antigen present on the surface of T lymphocytes.

[0087] The term “PD-1,” also known as CD279, PD1, or programmed cell death protein 1, refers to any natural PD-1 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats), particularly the human protein PD-1 with the amino acid sequence shown in UniProt (www.uniprot.org) accession number Q15116.

[0088] Unless otherwise specified, as used herein, the terms “interferon-γ”, or “IFNγ”, or “IFN-γ” refer to any naturally occurring IFNγ from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes unprocessed IFNγ as well as any form of IFNγ produced through cellular processing. The term also covers naturally occurring variants of IFNγ, such as splice variants or allelic variants.

[0089] Unless otherwise specified, as used herein, the terms “interleukin-2” or “IL-2” refer to any naturally occurring IL-2 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes unprocessed IL-2 as well as any form of IL-2 produced through cellular processing. The term also covers naturally occurring IL-2 variants, such as splice variants or allele variants.

[0090] Cytokine receptors are cell surface glycoproteins that specifically bind to cytokines and transduce their signals. Typically, cytokine receptors function as oligomeric complexes, usually composed of two to four receptor chains, also known as subunits, which can be identical or different. Therefore, the term "cytokine receptor complex" refers to a cytokine receptor composed of at least two subunits.

[0091] The IFNγ receptor complex comprises IFNγR1 and IFNγR2 subunits. Unless otherwise stated, the terms “interferon γ receptor 1” or “IFNγR1” (also known as CD119 (differentiation cluster 119) or interferon γ receptor α chain (IFNγRα)) refer to any naturally occurring IFNγR1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed IFNγR1, as well as any form of IFNγR1 produced through cellular processing. The term also covers naturally occurring IFNγR1 variants, such as splice variants or allelic variants. In some embodiments, the IFNγR1 is human IFNγR1.

[0092] Unless otherwise specified, as used herein, the terms "interferon gamma receptor 2" or "IFNγR2" refer to the interferon gamma receptor β chain (IFNγRβ), and any naturally occurring IFNγR2 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed IFNγR2, as well as any form of IFNγR2 produced through cellular processing. The term also covers naturally occurring IFNγR2 variants, such as splice variants or allele variants. In some embodiments, the IFNγR2 is human IFNγR2.

[0093] Unless otherwise specified, as used herein, the terms “IL-2Rα” or “α subunit of the IL-2 receptor” (also known as CD25) refer to any naturally occurring IL-2Rα from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed IL-2Rα, as well as any form of IL-2Rα produced through cellular processing. The term also covers naturally occurring variants of IL-2Rα, such as splice variants or allelic variants. In some embodiments, IL-2Rα is human IL-2Rα.

[0094] Unless otherwise specified, as used herein, the term "IL-2Rβ" or "β subunit of the IL-2 receptor" (also known as CD122 or p70) refers to any naturally occurring IL-2Rβ from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed IL-2Rβ, as well as any form of IL-2Rβ produced through cellular processing. The term also covers naturally occurring variants of IL-2Rβ, such as splice variants or allelic variants. In some embodiments, IL-2Rβ is human IL-2Rβ.

[0095] Unless otherwise specified, as used herein, the terms “IL-2Rγ” or “γ subunit of the IL-2 receptor” (also known as the γ subunit of common cytokine receptors, common γ chain, γc, or CD132) refer to any naturally occurring IL-2Rγ from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed IL-2Rγ, as well as any form of IL-2Rγ produced through cellular processing. The term also covers naturally occurring variants of IL-2Rγ, such as splice variants or allele variants. In some embodiments, IL-2Rγ is human IL-2Rγ.

[0096] Different associations of single IL-2R subunits IL-2Rα, IL-2Rβ, and IL-2Rγ can produce three forms of IL-2R with varying affinities for IL-2. High-affinity IL-2R refers to the heterotrimeric form of IL-2R, composed of IL-2Rα, IL-2Rβ, and IL-2Rγ. Intermediate-affinity IL-2R refers to the heterodimeric form of IL-2R, composed of IL-2Rβ and IL-2Rγ. However, low-affinity IL-2R refers to the monomeric form of IL-2R, composed only of IL-2Rα (see, for example, Olejniczak and Kasprzak, Med Sci Monit 14, RA179-189 (2008)).

[0097] The term "IL-2 receptor complex" as used in this article refers to a high-affinity IL-2 receptor or an intermediate-affinity IL-2 receptor.

[0098] The term "Fc domain" or "Fc region" used herein is used to define the C-terminal region of an immunoglobulin heavy chain that contains at least a portion of a constant region. This term includes both native sequence Fc regions and variant Fc regions. In one aspect, the human IgG heavy chain Fc region extends from Cys226 or Pro230 to the C-terminus of the heavy chain. However, antibodies produced by host cells can undergo post-translational cleavage of one or more (particularly one or two) amino acids from the C-terminus of the heavy chain. Therefore, antibodies produced by host cells by expressing a specific nucleic acid molecule encoding the full-length heavy chain can comprise the full-length heavy chain, or said antibodies can comprise cleaved variants of the full-length heavy chain. This could be the case where the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, according to the Kabat EU index number). Therefore, the C-terminal lysine (Lys447) or C-terminal glycine (Gly446) and lysine (Lys447) in the Fc region may or may not be present. In one aspect, a heavy chain comprising the Fc region (subunit) as specified herein is included in the binding molecule according to the invention, the heavy chain containing an additional C-terminal lysine (K447, according to the Kabat EU index number). In another aspect, a heavy chain comprising the Fc region (subunit) as specified herein is included in the binding molecule according to the invention, the heavy chain containing a C-terminal glycine residue (G446, according to the Kabat EU index number) but not a C-terminal lysine (Lys447). Unless otherwise specified herein, the amino acid residues in the Fc region or constant region are numbered according to the EU numbering system (also known as the EU index), as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991 (see also above). As used herein, the term "subunit" of the Fc domain refers to one of two polypeptides forming the dimer Fc domain, namely a polypeptide containing the C-terminal constant region of the immunoglobulin heavy chain that is stably self-associating. For example, the subunit of the IgG Fc domain contains the IgG CH2 and IgG CH3 constant domains.

[0099] "Modification that promotes association between the first and second subunits of the Fc domain" refers to manipulation of the peptide backbone or post-translational modification of the Fc domain subunits that reduces or prevents the association of a polypeptide containing an Fc domain subunit with the same polypeptide to form a homodimer. As used herein, "association-promoting modification" preferably includes individual modification of each of the two Fc domain subunits (i.e., the first and second subunits of the Fc domain) to which association is desired, wherein the modifications are complementary to each other to promote the association of the two Fc domain subunits. For example, association-promoting modification may alter the structure or charge of one or both of the Fc domain subunits to make their association sterically or electrostatically favorable, respectively. Thus, (hetero)dimerization occurs between a polypeptide containing the first Fc domain subunit and a polypeptide containing the second Fc domain subunit, which may differ with respect to additional components (e.g., antigen-binding domains) fused to each subunit. In one aspect, modifications that promote association between the first and second subunits of the Fc domain include amino acid mutations, particularly amino acid substitutions, in the Fc domain. In a particular aspect, modifications that promote association between the first and second subunits of the Fc domain include individual amino acid mutations, particularly amino acid substitutions, in each of the two subunits of the Fc domain.

[0100] One known heterodimerization method in the art is the so-called "mortar and pestle" technique, which is described in detail in several examples, such as WO96 / 027011; Ridgway, JB, et al., Protein Eng. 9 (1996) 617-621; Merchant, AM, et al., Nat. Biotechnol. 16 (1998) 677-681 and WO98 / 050431. In the "mortar and pestle" technique, within the interface formed between two CH3 domains in the antibody tertiary structure, specific amino acids on each CH3 domain are engineered to generate a protrusion ("mortar") in one CH3 domain and a cavity ("mortar") in the other CH3 domain, respectively. In the tertiary structure of a multispecific antibody, a protrusion introduced into one CH3 domain can be localized within a cavity introduced into another CH3 domain.

[0101] The term "effective function" refers to those biological activities attributable to the Fc region of an antibody that vary with antibody isotype. Examples of antibody effector functions include: C1q binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent phagocytosis (ADCP), cytokine secretion, antigen uptake by immune complex-mediated antigen-presenting cells, downregulation of cell surface receptors (e.g., B-cell receptors), and B-cell activation.

[0102] "Activating Fc receptors" are Fc receptors that, upon binding to the Fc domain of an antibody, trigger signal transduction events that stimulate effector functions in cells carrying the receptor. Human activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89).

[0103] Antibody-dependent cell-mediated cytotoxicity (ADCC) is an immune mechanism that causes immune effector cells to lyse antibody-coated target cells. Target cells are cells that specifically bind to an antibody or a derivative thereof containing the Fc region, typically via the N-terminal protein portion of the Fc region. As used herein, the term “reduced ADCC” is defined as a reduction in the number of target cells lysed within a given time period at a given antibody concentration in the culture medium surrounding the target cells via the ADCC mechanism defined above, and / or an increase in the antibody concentration necessary to achieve lysis of a given number of target cells within a given time period via the ADCC mechanism in the culture medium surrounding the target cells. Reduced ADCC is ADCC mediated by the same antibody produced from the same type of host cells but not engineered, using the same standard methods of production, purification, formulation, and storage (such methods are known to those skilled in the art). For example, reduced ADCC mediated by an antibody containing an amino acid substitution in the Fc domain that reduces ADCC is relative to ADCC mediated by the same antibody without that amino acid substitution in the Fc domain. Suitable methods for measuring ADCC are well known in the art (see, for example, PCT Publication No. WO 2006 / 082515 or PCT Publication No. WO 2012 / 130831).

[0104] "Reduced binding" (e.g., reduced binding to the Fc receptor) refers to a decrease in affinity for the corresponding interaction, as measured, for example, by SPR. For clarity, the term also includes reducing the affinity to zero (or below the detection limit of the analytical method), i.e., completely eliminating the interaction. Conversely, "increased binding" refers to an increase in binding affinity for the corresponding interaction.

[0105] “Affinity” refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise stated, as used herein, “binding affinity” refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of molecule X for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured by well-established methods known in the art, including those described herein. A preferred method for measuring affinity is surface plasmon resonance (SPR).

[0106] As used herein, the terms “engineering,” “engineered,” and “engineered modification” are considered to include any manipulation of the peptide backbone or post-translational modification of naturally occurring or recombinant peptides or fragments thereof. Engineering modification includes modifications to the amino acid sequence, glycosylation patterns, or side chain groups of individual amino acids, as well as combinations of these methods.

[0107] As used herein, the term "amino acid mutation" encompasses amino acid substitution, deletion, insertion, and modification. Any combination of substitution, deletion, insertion, and modification can be performed to obtain the final construct, provided that the final construct possesses the desired characteristics, such as reduced binding to the Fc receptor or increased association with another peptide. Amino acid sequence deletions and insertions include deletions and insertions of the amino-terminus and / or carboxyl-terminus of amino acids. Preferred amino acid mutations are amino acid substitutions. Non-conservative amino acid substitutions, i.e., replacing an amino acid with another amino acid having a different structure and / or chemical properties, are particularly preferred for the purpose of altering, for example, the binding characteristics of the Fc region. Amino acid substitutions include substitution with non-naturally occurring amino acids or with naturally occurring amino acid derivatives of the twenty standard amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be generated using genetic or chemical methods well known in the art. Genetic methods may include site-directed mutagenesis, PCR, gene synthesis, etc. It is also useful to consider methods that alter amino acid side chain groups by means other than genetic engineering, such as chemical modification. Various names may be used herein to refer to the same amino acid mutation. For example, replacing proline at position 329 of the Fc domain with glycine can be represented as 329G, G329, G329, P329G, or Pro329Gly.

[0108] The term "fusion" refers to the linking of components (such as Fab molecules and Fc domain subunits) directly or via one or more peptide linkers through peptide bonds.

[0109] The term "linker" or "peptide linker" refers to a peptide containing one or more amino acids, typically about 2 to 30 amino acids. Peptide linkers are known in the art or described herein. Suitable non-immunogenic linker peptides are, for example, (G4S)n peptide linkers, where G = glycine, S = serine, and where "n" is typically a number between 1 and 10. Additionally, the linker may contain a portion of an immunoglobulin hinge region. In particular, in the case of fusion of a Fab molecule with the N-terminus of an Fc domain subunit, fusion may be made via the immunoglobulin hinge region or a portion thereof.

[0110] The "percentage of amino acid sequence identity (%)" relative to a reference polypeptide sequence is defined as the percentage of amino acid residues in the candidate sequence that are identical to those in the reference polypeptide sequence after aligning the candidate sequence with the reference polypeptide sequence and introducing vacancies (if necessary) to achieve the maximum percentage of sequence identity, without considering any conserved substitutions as part of the sequence identity. Alignment used to determine the percentage of amino acid sequence identity can be performed in various ways within the scope of the art, such as using publicly available computer software, such as BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software, or the FASTA package. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithm required to achieve maximum alignment across the full length of the sequences being compared. Alternatively, the sequence comparison computer program ALIGN-2 can be used to generate the percentage of identity values. The ALIGN-2 sequence comparison computer program was written by Genentech, and the source code has been submitted with the user documentation to the US Copyright Office, Washington DC, 20559, registered under US Copyright Registry No. TXU510087 and described in WO 2001 / 007611.

[0111] Unless otherwise specified, for the purposes of this paper, amino acid sequence identity % values ​​were generated using the ggsearch program of FASTA package version 36.3.8c or later with the BLOSUM50 comparison matrix. The FASTA package was created by WR Pearson and DJ Lipman (“Improved Tools for Biological Sequence Analysis”, PNAS 85 (1988) 2444-2448); WR Pearson (“Effective protein sequence comparison” Meth. Enzymol. 266 (1996) 227-25 258); and Pearson et al. (Genomics 46 (1997) 24-36), and is publicly available at www.fasta.bioch.virginia.edu / fasta_www2 / fasta_down.shtml or www.ebi.ac.uk / Tools / sss / fasta.

[0112] Alternatively, sequences can be compared using a public server accessible at fasta.bioch.virginia.edu / fasta_www2 / index.cgi, using the ggsearch (global protein: protein) program with default options (BLOSUM50; open: -10; ext: -2; Ktup = 2) to ensure a global rather than local alignment. The percentage of amino acid identity is given in the output alignment header.

[0113] Cytokine mimics

[0114] The inventors have discovered that a pair of antigen-binding domains (hereinafter referred to as cytokine receptor-binding domains) capable of binding to different cytokine receptor subunits of a cytokine receptor complex can act as cytokine agonists, i.e., mimicking naturally occurring cytokines. Cytokine agonists are also known as cytokine mimics. This is demonstrated by combining a pair of cytokine receptor-binding domains capable of binding to different cytokine receptor subunits in a single antigen-binding molecule. The antibody form of these molecules provides advantageous properties compared to natural or recombinant cytokines. To achieve conditional activation of the cytokine receptor, the pair of cytokine receptor-binding domains is split into two distinct antigen-binding molecules, i.e., split molecules or split antibodies. These antigen-binding molecules also contain an antigen-binding domain capable of binding to a target antigen, hereinafter referred to as a target-binding domain. Through target-dependent assembly of this pair of cytokine receptor-binding domains, these molecules can act as cytokine mimics. The use of a target-dependent approach also allows the directing of agonistic activity to target sites, such as cells or tissues expressing the target. The target-binding domains of the molecules can bind the same target antigen simultaneously, i.e., they bind to different epitopes of said antigen and are non-competitive. This pair of target-binding domains is also called a dual complementary-site target-binding domain. Assembling the cytokine receptor-binding domain through dual complementary-site target-binding domains allows the cytokine receptor-binding domain to be specifically targeted to a target site, i.e., a cell or environment expressing the target antigen, to act as a cytokine mimic. Therefore, this pair of split antigen-binding molecules is a pair of dual complementary-site antigen-binding molecules. Finally, the pair of cytokine receptor-binding domains and target-binding domains are incorporated into a single molecule, hereinafter referred to as the integrated format. Target-independent assembly of the cytokine receptor-binding domains—that is, assembly in the absence of the target antigen—is prevented by keeping the cytokine receptor-binding domains far apart from each other. However, in the presence of the target antigen, the dual complementary-site assembly of the cytokine receptor-binding domains leads to the activation of the cytokine receptor.

[0115] Integrated format

[0116] The integrated format provides an antigen-binding molecule comprising i) a first target-binding domain, ii) a second target-binding domain, iii) a first cytokine receptor-binding domain, iv) a second cytokine receptor-binding domain, and v) an Fc domain, wherein the first target-binding domain can bind to a first epitope on the target antigen and the second target-binding domain can bind to a second epitope on the target antigen, wherein the first and second target-binding domains do not compete for binding on the target antigen; and wherein the first cytokine receptor-binding domain can bind to a first cytokine receptor subunit and the second cytokine receptor-binding domain can bind to a second cytokine receptor subunit.

[0117] Cytokine receptor binding domain

[0118] According to the present invention, the integrated antigen-binding molecule comprises a first cytokine receptor-binding domain and a second cytokine receptor-binding domain. The cytokine receptor-binding domains contained in the antigen-binding molecule bind to different cytokine receptor subunits. Each cytokine receptor-binding domain of the antigen-binding molecule binds to a different cytokine receptor subunit of the cytokine receptor complex. Therefore, the integrated antigen-binding molecule comprises a first cytokine receptor-binding domain capable of binding to a first cytokine receptor subunit and a second cytokine receptor-binding domain capable of binding to a second cytokine receptor subunit. The first and second cytokine receptor subunits are subunits of the cytokine receptor complex.

[0119] The cytokine receptor complex can be an IFNγ receptor complex, an IL-2 receptor complex, an IL-7 receptor complex, an IL-12 receptor complex, or an IL-18 receptor complex. Therefore, the first cytokine receptor-binding domain and the second cytokine receptor-binding domain can bind different subunits of the IFNγ receptor complex, IL-2 receptor complex, IL-7 receptor complex, IL-12 receptor complex, or IL-18 receptor complex. In one embodiment, the first cytokine receptor-binding domain and the second cytokine receptor-binding domain bind a subunit of the IFNγ receptor complex. Thus, in one embodiment, the first cytokine receptor-binding domain can bind IFNγR1 and the second cytokine receptor-binding domain can bind IFNγR2. Alternatively, the first cytokine receptor-binding domain can bind IFNγR2 and the second cytokine receptor-binding domain can bind IFNγR1. In another embodiment, the first cytokine receptor-binding domain and the second cytokine receptor-binding domain bind a subunit of the IL-2 receptor complex. Therefore, in one embodiment, the first cytokine receptor-binding domain is capable of binding IL-2Rβ and the second cytokine receptor-binding domain is capable of binding IL-2Rγ. In one embodiment, the first cytokine receptor-binding domain is capable of binding IL-2Rγ and the second cytokine receptor-binding domain is capable of binding IL-2Rβ. In another embodiment, the first and second cytokine receptor-binding domains bind to subunits of the IL-7 receptor complex. Therefore, in one embodiment, the first cytokine receptor-binding domain is capable of binding IL-7Ra and the second cytokine receptor-binding domain is capable of binding IL-2Rγ. In one embodiment, the first cytokine receptor-binding domain is capable of binding IL-2Rγ and the second cytokine receptor-binding domain is capable of binding IL-7Ra. In another embodiment, the first and second cytokine receptor-binding domains bind to subunits of the IL-12 receptor complex. Therefore, in one embodiment, the first cytokine receptor-binding domain is capable of binding IL-12Rβ1 and the second cytokine receptor-binding domain is capable of binding IL-12Rβ2. In one embodiment, the first cytokine receptor binding domain can bind IL-12Rβ2 and the second cytokine receptor binding domain can bind IL-12Rβ1.

[0120] The first and second cytokine receptor binding domains can be antibody fragments. In one embodiment, the first and second cytokine receptor binding domains are single-domain antibodies. In a specific embodiment, the first and second cytokine receptor binding domains are VHH domains.

[0121] In one aspect, the first cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, and the second cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. In another aspect, the first cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, and the second cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5. In yet another aspect, the first cytokine receptor-binding domain comprises the sequence of SEQ ID NO: 3, and the second cytokine receptor-binding domain comprises the sequence of SEQ ID NO: 7. In one aspect, the first cytokine receptor binding domain contains the sequence of SEQ ID NO: 7 and the second cytokine receptor binding domain contains the sequence of SEQ ID NO: 3.

[0122] In one aspect, the first cytokine receptor binding domain comprises an amino acid sequence selected from SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, and SEQ ID NO: 64, and the second cytokine receptor binding domain comprises an amino acid sequence selected from SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69. In another aspect, the first cytokine receptor binding domain comprises an amino acid sequence selected from SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, and the second cytokine receptor binding domain comprises an amino acid sequence selected from SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, and SEQ ID NO: 64. In one aspect, the first cytokine receptor binding domain comprises the sequence of SEQ ID NO: 64 and the second cytokine receptor binding domain comprises the sequence of SEQ ID NO: 66. In another aspect, the first cytokine receptor binding domain comprises the sequence of SEQ ID NO: 66 and the second cytokine receptor binding domain comprises the sequence of SEQ ID NO: 64.

[0123] Target antigen binding domain

[0124] According to the present invention, the antigen-binding molecule comprises a first target-binding domain and a second target-binding domain. Both the first and second target-binding domains bind to the same target, i.e., the same antigen. However, the first and second target-binding domains bind to different epitopes of the target. The first target-binding domain can bind to a first epitope on the target antigen, and the second target-binding domain can bind to a second epitope on the target antigen. The first and second target-binding domains can bind to the target simultaneously, i.e., the target-binding domain is a non-competitive domain. The first and second target-binding domains do not compete for binding to the target antigen.

[0125] The target binding domain of an antigen-binding molecule can be an antibody fragment. In one embodiment, the first target binding domain is an antibody fragment, and the second target binding domain is an antibody fragment. The first and / or second target binding domains can be Fv, Fab, scFv, scFab molecules, or single-domain antibodies. In one embodiment, the target binding domain is an Fv, Fab, scFv, scFab molecule, or a single-domain antibody, and the target binding domain is an Fv, Fab, scFv, scFab molecule, or a single-domain antibody.

[0126] In one embodiment, the first target-binding domain and the second target-binding domain are Fab molecules. In another embodiment, both the first and second target-binding domains are Fab molecules. In one embodiment, the first target-binding domain comprises a heavy chain variable domain (VH1), a light chain variable domain (VL1), a heavy chain constant domain (CH11), and a light chain constant domain (CL1). In another embodiment, the second target-binding domain comprises a heavy chain variable domain (VH2), a light chain variable domain (VL2), a heavy chain constant domain (CH12), and a light chain constant domain (CL2).

[0127] The target-binding domain can be a cross-Fab. In one embodiment, the first target-binding domain is a cross-Fab. In another embodiment, the second target-binding domain is a cross-Fab. In one embodiment, the first target-binding domain is a Fab molecule, wherein the Fab molecule is a cross-Fab, and the second target-binding domain is a Fab molecule, wherein the Fab molecule is not a cross-Fab. In one embodiment, the first target-binding domain is a Fab molecule, wherein the Fab molecule is a conventional Fab molecule, and the second target-binding domain is a Fab molecule, wherein the Fab molecule is a cross-Fab.

[0128] In one aspect, the Fab molecule contains charged modifications. To reduce mispairing of heavy and light chains from different Fab molecules, thereby improving the purity and yield of the desired antigen-binding molecule, the Fab molecule may contain different charged amino acid substitutions (so-called "charged modifications"). These modifications are introduced into the cross-Fab CH1 and CL domains or the conventional Fab CH1 and CL domains. In one particular aspect, the Fab molecule is such that the amino acid at position 123 (EU number) in the CL domain is replaced by arginine (R) and / or the amino acid at position 124 (EU number) is replaced by lysine (K); and the amino acid at position 147 (EU number) and / or position 213 (EU number) in the CH1 domain is replaced by glutamic acid (E). Preferably, the charge modifications are carried out in the conventional Fab molecule.

[0129] Charged modification can be introduced into the CH1 and CL domains of a Fab molecule with a first target-binding domain or a Fab molecule with a second target-binding domain. In one aspect, the first target-binding domain contains charge modification. In another aspect, the second target-binding domain contains charge modification. In yet another aspect, the first target-binding domain contains charge modification and the second target-binding domain contains cross-Fab. In a further aspect, the first target-binding domain contains cross-Fab, and the second target-binding domain contains charge modification.

[0130] Both the first and second target-binding domains specifically bind to the same target antigen. The target antigen can be a tumor-associated antigen or a T-cell antigen. The target antigen can be a tumor-associated antigen, such as CEA, FAP, Her2, Her3, or EGFR. Therefore, in one aspect, the first target-binding domain can bind to a first epitope of CEA, and the second target-binding domain can bind to a second epitope of CEA. In one aspect, the first target-binding domain can bind to a first epitope of FAP, and the second target-binding domain can bind to a second epitope of FAP. In one aspect, the first target-binding domain can bind to a first epitope of Her2, and the second target-binding domain can bind to a second epitope of Her2. In one aspect, the first target-binding domain can bind to a first epitope of Her3, and the second target-binding domain can bind to a second epitope of Her3. In one aspect, the first target-binding domain can bind to a first epitope of EGFR, and the second target-binding domain can bind to a second epitope of EGFR.

[0131] In one aspect, the first target-binding domain comprises VH1 of SEQ ID NO: 20 and VL1 of SEQ ID NO: 21, and the second target-binding domain comprises VH2 of SEQ ID NO: 22 and VL2 of SEQ ID NO: 23. In another aspect, the first target-binding domain comprises VH1 of SEQ ID NO: 22 and VL1 of SEQ ID NO: 23, and the second target-binding domain comprises VH2 of SEQ ID NO: 20 and VL2 of SEQ ID NO: 21.

[0132] The target antigen may be a T-cell antigen, such as PD-1 or LAG-3. The target antigen may be human PD-1 or human LAG-3. Therefore, in one aspect, the first target-binding domain is capable of binding to a first epitope of PD-1, and the second target-binding domain is capable of binding to a second epitope of PD-1. In one aspect, the first target-binding domain is capable of binding to a first epitope of LAG-3, and the second target-binding domain is capable of binding to a second epitope of LAG-3. In one aspect, the first target-binding domain comprises VH1 of SEQ ID NO: 80 and VL1 of SEQ ID NO: 81, and the second target-binding domain comprises VH2 of SEQ ID NO: 82 and VL2 of SEQ ID NO: 83. In one aspect, the first target-binding domain comprises VH1 of SEQ ID NO: 82 and VL1 of SEQ ID NO: 83, and the second target-binding domain comprises VH2 of SEQ ID NO: 80 and VL2 of SEQ ID NO: 81. In another aspect, the first target-binding domain comprises VH1 of SEQ ID NO: 82 and VL1 of SEQ ID NO: 83, and the second target-binding domain comprises VH2 of SEQ ID NO: 140 and VL2 of SEQ ID NO: 141. In yet another aspect, the first target-binding domain comprises VH1 of SEQ ID NO: 140 and VL1 of SEQ ID NO: 141, and the second target-binding domain comprises VH2 of SEQ ID NO: 82 and VL2 of SEQ ID NO: 83.

[0133] Fc structural domain

[0134] According to the present invention, the antigen-binding molecule contains an Fc domain.

[0135] The Fc domain of a binding molecule consists of a pair of polypeptide chains, a first Fc domain subunit, and a second Fc domain subunit. Both the first and second Fc domain subunits may contain the heavy chain domain of an immunoglobulin molecule. For example, the Fc domain of the immunoglobulin G (IgG) molecule is a dimer, with each subunit containing the CH2 and CH3 IgG heavy chain constant domains. The two subunits of the Fc domain can stably associate with each other.

[0136] In one aspect, the antigen-binding molecule comprises an Fc domain consisting of a first Fc domain subunit and a second Fc domain subunit. In a particular aspect, the antigen-binding molecule comprises no more than one Fc domain.

[0137] In one respect, the Fc domain of the antigen-binding molecule is the IgG Fc domain. In a particular respect, the Fc domain is the IgG1 Fc domain. In other respects, the Fc domain is the IgG4 Fc domain.

[0138] In a more specific aspect, the Fc domain is the IgG4 Fc domain containing an amino acid substitution (specifically, amino acid substitution S228P) at position S228 (Kabat EU index number). This amino acid substitution reduces in vivo Fab arm exchange of IgG4 antibodies (see Stubenrauch et al., Drug Metabolism and Disposition 38, 84-91 (2010)). In a further aspect, the Fc domain is the human Fc domain. In a particular aspect, the Fc domain is the IgG1 Fc domain.

[0139] In one aspect, the Fc domain includes modifications that promote the association of the first and second subunits of the Fc domain. The Fc domain modifications that promote heterodimerization are further described below.

[0140] In one aspect, the Fc domain contains one or more amino acid substitutions that reduce Fc receptor binding and / or effector function. Fc domain modifications that reduce Fc receptor binding and / or effector function are further described below.

[0141] Fc domain modification that promotes heterodimerization

[0142] The antigen-binding molecule according to the invention comprises two target-binding domains and two cytokine receptor-binding domains, which can be fused to a first or second Fc domain subunit, thus these two Fc domain subunits are typically contained in two different polypeptide chains. Recombinant co-expression of these polypeptides and subsequent dimerization result in several possible combinations of the two polypeptides. To improve the yield and purity of the antigen-binding molecule in recombinant production, it is therefore advantageous to introduce modifications into the Fc domains of the antigen-binding molecule that promote the association of the desired polypeptide.

[0143] Therefore, in a particular aspect, the Fc domain of the antigen-binding molecule according to the invention comprises modifications that promote association between the first and second subunits of the Fc domain. The most extensive protein-protein interaction site between the two subunits of the human IgG Fc domain is in the CH3 domain of the Fc domain. Therefore, in one aspect, the modification is in the CH3 domain of the Fc domain.

[0144] Several methods exist for modifying the CH3 domain of the Fc domain to achieve heterodimerization, and these methods are described in detail, for example, in WO 96 / 27011, WO 98 / 050431, EP 1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012058768, WO2013157954, and WO 2013096291. Typically, in all such methods, the CH3 domains of the first subunit of the Fc domain and the CH3 domains of the second subunit of the Fc domain are engineered in a complementary manner, such that each CH3 domain (or the heavy chain containing it) is no longer homodimerized with itself, but is forced to heterodimerize with the other complementaryly engineered CH3 domains (so that the first and second CH3 domains heterodimerize and do not form homodimers between the two first or two second CH3 domains).

[0145] In a specific aspect, the modification that promotes the association of the first and second subunits of the Fc domain is a so-called "mortar and pestle structure" modification, which includes a "mortar" modification in one of the two subunits of the Fc domain and a "mortar" modification in the other of the two subunits of the Fc domain.

[0146] The pestle-and-mortar structure technique is described, for example, in US 5,731,168; US 7,695,936; Ridgway et al., ProtEng 9,617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Typically, this method involves introducing a protrusion (“pestle”) at the interface of a first polypeptide and a corresponding cavity (“mortar”) at the interface of a second polypeptide, such that the protrusion can be positioned within the cavity to promote the formation of a heterodimer and inhibit the formation of a homodimer. The protrusion is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan).

[0147] Compensating cavities of the same or similar size as the protrusions are created at the interface of the second polypeptide by replacing large amino acid side chains with smaller amino acid side chains (e.g., alanine or threonine).

[0148] Therefore, in a preferred aspect, in the CH3 domain of the first subunit of the Fc domain of the antigen-binding molecule, amino acid residues are replaced by amino acid residues with larger side chain volumes, thereby creating a protrusion in the CH3 domain of the first subunit, which can be positioned in a cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain, amino acid residues are replaced by amino acid residues with smaller side chain volumes, thereby creating a cavity within the CH3 domain of the second subunit, in which the protrusion in the CH3 domain of the first subunit can be positioned.

[0149] Preferably, the amino acid residues with larger side chain volumes are selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), and tryptophan (W). Preferably, the amino acid residues with smaller side chain volumes are selected from the group consisting of alanine (A), serine (S), threonine (T), and valine (V). Protrusions and cavities can be prepared by altering the nucleic acid encoding the polypeptide, for example, through site-specific mutagenesis or peptide synthesis.

[0150] Specifically, in the first subunit (“mortar” subunit) of the Fc domain (CH3 domain), the threonine residue at position 366 is replaced by a tryptophan residue (T366W), and in the second subunit (“mortar” subunit) of the Fc domain (CH3 domain), the tyrosine residue at position 407 is replaced by a valine residue (Y407V). In another aspect, in the second subunit of the Fc domain, additionally, the threonine residue at position 366 is replaced by a serine residue (T366S), and the leucine residue at position 368 is replaced by an alanine residue (L368A) (according to the Kabat EU index number).

[0151] In another aspect, in the first subunit of the Fc domain, the serine residue at position 354 is replaced by a cysteine ​​residue (S354C) or the glutamate residue at position 356 is replaced by a cysteine ​​residue (E356C) (especially the serine residue at position 354 being replaced by a cysteine ​​residue), and in the second subunit of the Fc domain, the tyrosine residue at position 349 is replaced by a cysteine ​​residue (Y349C) (according to Kabat).

[0152] (EU index number). The introduction of these two cysteine ​​residues leads to the formation of a disulfide bridge between the two subunits of the Fc domain, thereby further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).

[0153] In certain respects, the first subunit of the Fc domain contains amino acid substitutions S354C and T366W, and the second subunit of the Fc domain contains amino acid substitutions Y349C, T366S, L368A, and Y407V (according to Kabat EU index numbers).

[0154] Other CH3 modification techniques for implementing heterodimerization are contemplated as alternatives to those described in the present invention, and are described, for example, in WO 96 / 27011, WO 98 / 050431, EP 1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012 / 058768, WO 2013 / 157954, and WO 2013 / 096291.

[0155] In one respect, the heterodimerization method described in EP 1870459 can be used alternatively. This method is based on introducing charged amino acids with opposite charges at specific amino acid positions in the CH3 / CH3 domain interface between the two subunits of the Fc domain.

[0156] One specific aspect of the antigen-binding molecule of the present invention is the amino acid mutation R409D; K370E in one of the two CH3 domains (of the Fc domain); and the amino acid mutation D399K; and E357K (according to the Kabat EU index number) in the other CH3 domain of the Fc domain.

[0157] In one aspect, the antigen-binding molecule of the present invention comprises an amino acid mutation T366W in the CH3 domain of the first subunit of the Fc domain and amino acid mutations T366S, L368A, Y407V in the CH3 domain of the second subunit of the Fc domain, and additionally an amino acid mutation R409D; K370E in the CH3 domain of the first subunit of the Fc domain, and an amino acid mutation D399K; and E357K (according to Kabat EU index number) in the CH3 domain of the second subunit of the Fc domain.

[0158] In one aspect, the antigen-binding molecule of the present invention comprises amino acid mutations S354C, T366W in the CH3 domain of the first subunit of the Fc domain and amino acid mutations Y349C, T366S, L368A, Y407V in the CH3 domain of the second subunit of the Fc domain, or the antigen-binding molecule comprises amino acid mutations Y349C, T366W in the CH3 domain of the first subunit of the Fc domain and amino acid mutations S354C, T366S, L368A, Y407V in the CH3 domain of the second subunit of the Fc domain, and additionally amino acid mutation R409D; K370E in the CH3 domain of the first subunit of the Fc domain, and amino acid mutation D399K; and E357K in the CH3 domain of the second subunit of the Fc domain (all according to Kabat EU index numbers).

[0159] In one aspect, the heterodimerization method described in WO 2013 / 157953 may be used alternatively. In one aspect, the first CH3 domain contains the amino acid mutation T366K, and the second CH3 domain contains the amino acid mutation L351D (numbered according to the Kabat EU index). In a further aspect, the first CH3 domain contains an additional amino acid mutation L351K. In a further aspect, the second CH3 domain also contains amino acid mutations selected from the group consisting of Y349E, Y349D, and L368E (especially L368E) (numbered according to the Kabat EU index).

[0160] In one aspect, the heterodimerization method described in WO 2012 / 058768 may be used alternatively. In one aspect, the first CH3 domain comprises amino acid mutations L351Y and Y407A, and the second CH3 domain comprises amino acid mutations T366A and K409F. In a further aspect, the second CH3 domain includes further amino acid mutations at positions T411, D399, S400, F405, N390, or K392, selected from the group consisting of: a) T411N, T411R, T411Q, T411K, T411D, T411E, or T411W; b) D399R, D399W, D399Y, or D399K; c) S400E, S400D, S400R, or S400K; d) F405I, F405M, F405T, F405S, F405V, or F405W; e) N390R, N390K, or N390D; f) K392V, K392M, K392R, K392L, or K392F. Or K392E (according to Kabat EU index number). In a further aspect, the first CH3 domain contains the amino acid mutations L351Y and Y407A, and the second CH3 domain contains the amino acid mutations T366V and K409F. In a further aspect, the first CH3 domain contains the amino acid mutation Y407A, and the second CH3 domain contains the amino acid mutations T366A and K409F. In a further aspect, the second CH3 domain also contains the amino acid mutations K392E, T411E, D399R, and S400R (according to Kabat EU index number).

[0161] In one respect, the heterodimerization method described in WO 2011 / 143545 can be used alternatively, for example, by modifying amino acids at positions selected from the group consisting of 368 and 409 (according to the Kabat EU index number).

[0162] In one aspect, the heterodimerization method described in WO 2011 / 090762 can be used alternatively, which also employs the aforementioned mortar and pestle structure technique. In one aspect, the first CH3 domain contains the amino acid mutation T366W, and the second CH3 domain contains the amino acid mutation Y407A. In another aspect, the first CH3 domain contains the amino acid mutation T366Y, and the second CH3 domain contains the amino acid mutation Y407T (numbered according to the Kabat EU index).

[0163] In one aspect, the antigen-binding molecule or its Fc domain is an IgG2 subclass, and alternatively, the heterodimerization method described in WO2010 / 129304 is used.

[0164] In an alternative approach, modifications that promote association between the first and second subunits of the Fc domain include modifications that mediate electrostatic reorientation effects, such as those described in PCT Publication WO 2009 / 089004. Typically, this method involves replacing one or more amino acid residues at the interface between the two Fc domain subunits with charged amino acid residues, making homodimer formation electrostatically unfavorable but heterodimerization electrostatically favorable. In some aspects, the first CH3 domain comprises an amino acid substitution of K392 or N392 with a negatively charged amino acid (e.g., glutamic acid (E) or aspartic acid (D), particularly K392D or N392D), and the second CH3 domain comprises an amino acid substitution of D399, E356, D356, or E357 with a positively charged amino acid (e.g., lysine (K) or arginine (R), particularly D399K, E356K, D356K, or E357K, more particularly D399K and E356K). In a further aspect, the first CH3 domain also comprises an amino acid substitution of K409 or R409 with a negatively charged amino acid (e.g., glutamic acid (E) or aspartic acid (D), particularly K409D or R409D). In a further aspect, the first CH3 domain may further or alternatively contain amino acid substitutions for K439 and / or K370 with negatively charged amino acids (e.g., glutamic acid (E) or aspartic acid (D)) (all according to Kabat EU index numbers).

[0165] In one aspect, the heterodimerization method described in WO 2007 / 147901 may be used alternatively. In one aspect, the first CH3 domain comprises amino acid mutations K253E, D282K, and K322D, and the second CH3 domain comprises amino acid mutations D239K, E240K, and K292D (according to Kabat EU index numbers). In one aspect, the heterodimerization method described in WO 2007 / 110205 may be used alternatively.

[0166] In one aspect, the first subunit of the Fc domain contains amino acid substitutions of K392D and K409D, and the second subunit of the Fc domain contains amino acid substitutions of D356K and D399K (according to the Kabat EU index number).

[0167] Fc domain modifications that reduce Fc receptor binding and / or effector function

[0168] The Fc domain endows antigen-binding molecules with favorable pharmacokinetic properties, including a long serum half-life that facilitates good accumulation in target tissues and a favorable tissue-to-blood partition ratio. However, it can also lead to the binding molecule undesirably targeting cells expressing Fc receptors instead of preferred antigen-carrying cells. Furthermore, co-activation of the Fc receptor signaling pathway can lead to cytokine release, potentially resulting in overactivation of cytokine receptors and severe side effects with systemic administration. Activation of immune cells other than T cells (carrying Fc receptors) may even reduce the efficacy of the antigen-binding molecule due to its potential destruction of T cells (e.g., via NK cells).

[0169] Therefore, in certain aspects, the Fc domain of the antigen-binding molecule according to the invention exhibits reduced binding affinity to the Fc receptor and / or reduced effector function compared to the native IgG1 Fc domain. In some such aspects, the Fc domain (or the antigen-binding molecule containing said Fc domain) exhibits binding affinity less than 50%, particularly less than 20%, more particularly less than 10%, and most particularly less than 5%, compared to the native IgG1 Fc domain (or the antigen-binding molecule containing said Fc domain), and / or effector function less than 50%, particularly less than 20%, more particularly less than 10%, and most particularly less than 5%, compared to the native IgG1 Fc domain (or the antigen-binding molecule containing said Fc domain). In one aspect, the Fc domain (or the antigen-binding molecule containing said Fc domain) substantially does not bind to the Fc receptor and / or induce effector function. In one respect, the Fc receptor is an Fcγ receptor. In another respect, the Fc receptor is a human Fc receptor. In another respect, the Fc receptor is an activating Fc receptor. In a specific respect, the Fc receptor is an activating human Fcγ receptor, more specifically human FcγRIIIa, FcγRI, or FcγRIIa, most specifically human FcγRIIIa. In one respect, the effector function is one or more effector functions selected from the group consisting of CDC, ADCC, ADCP, and cytokine secretion. In a specific respect, the effector function is ADCC. In one respect, the Fc domain exhibits a substantially similar binding affinity to the nascent Fc receptor (FcRn) compared to the native IgG1 Fc domain. When the Fc domain (or an antigen-binding molecule containing the Fc domain) exhibits a binding affinity for FcRn greater than about 70%, particularly greater than about 80%, and even more particularly greater than about 90% for the native IgG1 Fc domain (or an antigen-binding molecule containing the native IgG1 Fc domain), substantially similar binding to FcRn is achieved.

[0170] In some respects, the Fc domain is engineered to have reduced binding affinity for the Fc receptor and / or reduced effector function compared to an unengineered Fc domain. In a particular respect, the Fc domain of the antigen-binding molecule contains one or more amino acid mutations that reduce the binding affinity of the Fc domain to the Fc receptor and / or effector function. Typically, the same one or more amino acid mutations are present in each of the two subunits of the Fc domain. In one respect, the amino acid mutation reduces the binding affinity of the Fc domain to the Fc receptor. In another respect, the amino acid mutation reduces the binding affinity of the Fc domain to the Fc receptor by at least 2-fold, at least 5-fold, or at least 10-fold. In the respect where more than one amino acid mutation reducing the binding affinity of the Fc domain to the Fc receptor is present, the combination of these amino acid mutations can reduce the binding affinity of the Fc domain to the Fc receptor by at least 10-fold, at least 20-fold, or even at least 50-fold. In one aspect, antigen-binding molecules containing engineered Fc domains exhibit a binding affinity to Fc receptors of less than 20%, particularly less than 10%, and more particularly less than 5%, compared to antigen-binding molecules containing unengineered Fc domains. In a particular aspect, the Fc receptor is an Fcγ receptor. In one aspect, the Fc receptor is a human Fc receptor. In one aspect, the Fc receptor is an activated Fc receptor. In a specific aspect, the Fc receptor is an activated human Fcγ receptor, more specifically human FcγRIIIa, FcγRI, or FcγRIIa, most specifically human FcγRIIIa. Preferably, binding affinity to each of these receptors is reduced. In one aspect, binding affinity to complementary components, particularly specific binding affinity to C1q, is also reduced. In one aspect, binding affinity to nascent Fc receptors (FcRn) is not reduced.

[0171] When the Fc domain (or an antigen-binding molecule containing the Fc domain) exhibits a binding affinity for FcRn greater than about 70% for the unengineered form of the Fc domain (or an antigen-binding molecule containing the unengineered form of the Fc domain), substantially similar binding to FcRn is achieved, i.e., the binding affinity of the Fc domain for the receptor is maintained. The Fc domain or the antigen-binding molecule of the present invention containing the Fc domain can exhibit such an affinity greater than about 80% or even greater than about 90%. In some aspects, the Fc domain of the antigen-binding molecule is engineered to have reduced effector function compared to the unengineered Fc domain. Reduced effector functions may include, but are not limited to, one or more of the following: reduced complement-dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen uptake by antigen-presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signal transduction-induced apoptosis, reduced cross-linking of target-binding antibodies, reduced dendritic cell maturation, or reduced T cell sensitization. In one aspect, a reduced effector function is one or more of the reduced effector functions selected from the group consisting of reduced CDC, reduced ADCC, reduced ADCP, and reduced cytokine secretion. In a particular aspect, a reduced effector function is reduced ADCC. In one aspect, reduced ADCC is less than 20% of ADCC induced by an unengineered Fc domain (or a binding molecule containing an unengineered Fc domain).

[0172] In one aspect, an amino acid mutation that reduces the binding affinity of the Fc domain to the Fc receptor and / or the function of the effector is an amino acid substitution. In another aspect, the Fc domain contains an amino acid substitution at a position selected from the group consisting of E233, L234, L235, N297, P331, and P329 (according to Kabat EU index numbers). In a more specific aspect, the Fc domain contains an amino acid substitution at a position selected from the group consisting of L234, L235, and P329 (according to Kabat EU index numbers). In one aspect, the Fc domain contains amino acid substitutions L234A and L235A (according to Kabat EU index numbers). In some such aspects, the Fc domain is the IgG1 Fc domain, particularly the human IgG1 Fc domain. In one aspect, the Fc domain contains an amino acid substitution at position P329. In a more specific aspect, the amino acid substitution is P329A or P329G, particularly P329G (according to the Kabat EU index number). In one aspect, the Fc domain contains an amino acid substitution at position P329 and additional amino acid substitutions at positions selected from E233, L234, L235, N297, and P331 (according to the Kabat EU index number). In a more specific aspect, the additional amino acid substitutions are E233P, L234A, L235A, L235E, N297A, N297D, or P331S. In a particular aspect, the Fc domain contains amino acid substitutions at positions P329, L234, and L235 (according to the Kabat EU index number). In a more specific aspect, the Fc domain contains amino acid mutations L234A, L235A, and P329G (“P329G LALA”, “PGLALA”, or “LALAPG”). Specifically, in certain aspects, each subunit of the Fc domain contains amino acid substitutions L234A, L235A, and P329G (Kabat EU index number), that is, in each of the first and second subunits of the Fc domain, the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced with a glycine residue (P329G) (according to the Kabat EU index number).

[0173] In some of these respects, the Fc domain is the IgG1 Fc domain, particularly the human IgG1 Fc domain. The amino acid-substituted “P329G LALA” combination almost completely eliminates Fcγ receptor (and complement) binding of the human IgG1 Fc domain, as described in PCT Publication No. WO 2012 / 130831, the entire contents of which are incorporated herein by reference. WO 2012 / 130831 also describes methods for preparing such mutant Fc domains and methods for determining their properties, such as Fc receptor binding or effector function.

[0174] Compared to IgG1 antibodies, IgG4 antibodies exhibit reduced binding affinity to the Fc receptor and reduced effector function. Therefore, in one aspect, the Fc domain of the binding molecule of the present invention is an IgG4 Fc domain, particularly a human IgG4 Fc domain. In one aspect, the IgG4 Fc domain contains an amino acid substitution at position S228, particularly amino acid substitution S228P (according to Kabat EU index number). To further reduce its binding affinity to the Fc receptor and / or its effector function, in one aspect, the IgG4 Fc domain contains an amino acid substitution at position L235, particularly amino acid substitution L235E (according to Kabat EU index number). In one aspect, the IgG4 Fc domain contains an amino acid substitution at position P329, particularly amino acid substitution P329G (according to Kabat EU index number). In a preferred aspect, the IgG4 Fc domain comprises amino acid substitutions at positions S228, L235, and P329, particularly S228P, L235E, and P329G (according to Kabat EU index numbers). Such IgG4 Fc domain mutants and their Fcγ receptor-binding properties are described in PCT Publication No. WO 2012 / 130831, the entire contents of which are incorporated herein by reference.

[0175] In certain respects, Fc domains exhibiting reduced binding affinity to Fc receptors and / or reduced effector function compared to native IgG1 Fc domains are human IgG1 Fc domains containing amino acid substitutions of L234A, L235A, and optionally P329G, or human IgG4 Fc domains containing amino acid substitutions of S228P, L235E, and optionally P329G (according to Kabat EU index number).

[0176] In some respects, N-glycosylation of the Fc domain has been eliminated. In some of these respects, the Fc domain contains an amino acid mutation at position N297, specifically replacing the amino acid substitution of asparagine with alanine (N297A) or aspartic acid (N297D) (according to the Kabat EU index number).

[0177] In addition to the Fc domains described above and in PCT Publication WO 2012 / 130831, Fc domains with reduced Fc receptor binding and / or decreased effector function also include those Fc domains with substitutions for one or more of Fc domain residues 238, 265, 269, 270, 297, 327, and 329 (US Patent No. 6,737,056) (according to Kabat's EU Index No.). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc mutant, in which residues 265 and 297 are substituted with alanine (US Patent No. 7,332,581).

[0178] Mutant Fc domains can be prepared using genetic or chemical methods well-known in the art, through amino acid deletion, substitution, insertion, or modification. Genetic methods may include site-specific mutagenesis of the coding DNA sequence, PCR, gene synthesis, etc. Correct nucleotide changes can be verified, for example, by sequencing.

[0179] Binding to Fc receptors can be readily determined, for example, by ELISA or by surface plasmon resonance (SPR) using standard instruments such as the BIAcore instrument (GE Healthcare), and Fc receptors can be obtained, for example, through recombinant expression. Alternatively, the binding affinity of Fc domains or binding molecules containing Fc domains to Fc receptors can be assessed using cell lines known to express specific Fc receptors, such as human NK cells expressing the FcγIIIa receptor.

[0180] The effector function of the Fc domain or a binding molecule containing an Fc domain can be measured by methods known in the art. Examples of in vitro assays for evaluating the ADCC activity of a target molecule are described in U.S. Patent No. 5,500,362; Hellstrom et al., Proc Natl Acad Sci USA 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA 82, 1499-1502 (1985); U.S. Patent No. 5,821,337; Bruggemann et al., J Exp Med 166, 1351-1361 (1987).

[0181] Alternatively, non-radioactive assays can be used (see, for example, the ACTI™ non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA); and the CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells.

[0182] Alternatively or otherwise, the ADCC activity of the target molecule can be assessed in vivo in animal models such as those disclosed in Clynes et al., Proc Natl Acad Sci USA 95,652-656 (1998).

[0183] In one aspect, the binding of the Fc domain to complement components, particularly C1q, is reduced. Therefore, in one aspect, the Fc domain is engineered to have reduced effector functions, including reduced CDC. C1q binding assays can be performed to determine whether the Fc domain, or an antigen-binding molecule containing the Fc domain, is capable of binding C1q and thus possesses CDC activity. See, for example, C1q and C3c binding ELISAs in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activation, a CDC assay can be performed (see, for example, Gazzano-Santoro et al., J Immunol Methods 202, 163 (1996); Cragg et al., Blood 101, 1045-1052 (2003); and Cragg and Glennie, Blood 103, 2738-2743 (2004)).

[0184] FcRn binding and in vivo clearance / half-life determinations can also be performed using methods known in the art (see, for example, Petkova, SB et al., Int'l. Immunol. 18(12):1759-1769 (2006); WO 2013 / 120929).

[0185] Integrated format configuration

[0186] The antigen-binding molecule according to the present invention can have various molecular configurations, that is, the domains of the binding molecule can be connected to each other in different ways.

[0187] The integrated antigen-binding molecule comprises a first target-binding domain and a second target-binding domain, a first cytokine receptor-binding domain and a second cytokine receptor-binding domain, and a first Fc domain subunit and a second Fc domain subunit. In one particular aspect, one target-binding domain and one cytokine receptor-binding domain are fused to one of the Fc domain subunits, and another target-binding domain and cytokine receptor-binding domain are fused to another Fc domain subunit. The cytokine receptor-binding domain may fuse at its C-terminus to the N-terminus of the target-binding domain. The target-binding domain may fuse at its N-terminus or its C-terminus to the C-terminus or N-terminus of one of the Fc domain subunits, respectively.

[0188] In one aspect, the target-binding domain is a Fab molecule. Therefore, the first target-binding domain may comprise a heavy chain variable domain (VH1), a light chain variable domain (VL1), a heavy chain constant domain (CH11), and a light chain constant domain (CL1), and the second target-binding domain may comprise a heavy chain variable domain (VH2), a light chain variable domain (VL2), a heavy chain constant domain (CH12), and a light chain constant domain (CL2). In one aspect, the first target-binding domain and / or the second target-binding domain are cross-Fab molecules. In one aspect, the first target-binding domain is a cross-Fab molecule. In one aspect, the second target-binding domain is a cross-Fab molecule. In one aspect, the antigen-binding molecule comprises a first target-binding domain and a second target-binding domain, wherein the first target-binding domain is a cross-Fab molecule, and the second target-binding domain is a conventional Fab molecule. In one aspect, the antigen-binding molecule comprises a first target-binding domain and a second target-binding domain, wherein the first target-binding domain is a conventional Fab molecule, and the second target-binding domain is a cross-Fab molecule.

[0189] In one aspect, the antigen-binding molecule comprises a first cytokine-receptor binding domain fused at its C-terminus to the N-terminus of a first target-binding domain of VH1 or VL1, and the first target-binding domain fused at the N-terminus of its VH1 or VL1 to the C-terminus of a first Fc domain subunit, and a second cytokine-receptor binding domain fused at its C-terminus to the N-terminus of a second target-binding domain of VH2 or VL2, and the second target-binding domain fused at the C-terminus of its CH12 to the N-terminus of a second Fc domain subunit.

[0190] In one aspect, the antigen-binding molecule comprises a first polypeptide comprising a first Fc domain subunit, VH1, and CH11 in sequence from the N-terminus to the C-terminus; a second polypeptide comprising a first cytokine receptor-binding domain, VL1, and CL1 in sequence from the N-terminus to the C-terminus; a third polypeptide comprising VL2, CH12, and a second Fc domain subunit in sequence from the N-terminus to the C-terminus; and a fourth polypeptide comprising a second cytokine receptor-binding domain, VH2, and CL2 in sequence from the N-terminus to the C-terminus.

[0191] In one aspect, the antigen-binding molecule comprises a first polypeptide comprising a first Fc domain subunit, VL1, and CH11 in sequence from the N-terminus to the C-terminus; a second polypeptide comprising a first cytokine receptor-binding domain, VH1, and CL1 in sequence from the N-terminus to the C-terminus; a third polypeptide comprising VH2, CH12, and a second Fc domain subunit in sequence from the N-terminus to the C-terminus; and a fourth polypeptide comprising a second cytokine receptor-binding domain, VL2, and CL2 in sequence from the N-terminus to the C-terminus.

[0192] In one aspect, the antigen-binding molecule comprises a first polypeptide comprising a first Fc domain subunit, VL1, and CL1 in sequence from the N-terminus to the C-terminus; a second polypeptide comprising a first cytokine receptor-binding domain, VH1, and CH11 in sequence from the N-terminus to the C-terminus; a third polypeptide comprising VL2, CH12, and a second Fc domain subunit in sequence from the N-terminus to the C-terminus; and a fourth polypeptide comprising a second cytokine receptor-binding domain, VH2, and CL2 in sequence from the N-terminus to the C-terminus.

[0193] In one aspect, the antigen-binding molecule comprises a first polypeptide comprising a first Fc domain subunit, VH1, and CL1 in sequence from the N-terminus to the C-terminus; a second polypeptide comprising a first cytokine receptor-binding domain, VL1, and CH11 in sequence from the N-terminus to the C-terminus; a third polypeptide comprising VH2, CH12, and a second Fc domain subunit in sequence from the N-terminus to the C-terminus; and a fourth polypeptide comprising a second cytokine receptor-binding domain, VL2, and CL2 in sequence from the N-terminus to the C-terminus.

[0194] In one aspect, the antigen-binding molecule comprises a first polypeptide comprising a first Fc domain subunit, VH1, and CH11 in sequence from the N-terminus to the C-terminus; a second polypeptide comprising a first cytokine receptor-binding domain, VL1, and CL1 in sequence from the N-terminus to the C-terminus; a third polypeptide comprising a second cytokine receptor-binding domain, VL2, CH12, and a second Fc domain subunit in sequence from the N-terminus to the C-terminus; and a fourth polypeptide comprising VH2 and CL2 in sequence from the N-terminus to the C-terminus.

[0195] In one aspect, the antigen-binding molecule comprises a first polypeptide comprising a first Fc domain subunit, VL1, and CH11 in sequence from the N-terminus to the C-terminus; a second polypeptide comprising a first cytokine receptor-binding domain, VH1, and CL1 in sequence from the N-terminus to the C-terminus; a third polypeptide comprising a second cytokine receptor-binding domain, VH2, CH12, and a second Fc domain subunit in sequence from the N-terminus to the C-terminus; and a fourth polypeptide comprising VL2 and CL2 in sequence from the N-terminus to the C-terminus.

[0196] In one aspect, the antigen-binding molecule comprises a first polypeptide comprising a first Fc domain subunit, VL1, and CL1 in sequence from the N-terminus to the C-terminus; a second polypeptide comprising a first cytokine receptor-binding domain, VH1, and CH11 in sequence from the N-terminus to the C-terminus; a third polypeptide comprising a second cytokine receptor-binding domain, VL2, CH12, and a second Fc domain subunit in sequence from the N-terminus to the C-terminus; and a fourth polypeptide comprising VH2 and CL2 in sequence from the N-terminus to the C-terminus.

[0197] In one aspect, the antigen-binding molecule comprises a first polypeptide containing a first Fc domain subunit, VH1, and CL1 in sequence from the N-terminus to the C-terminus; a second polypeptide containing a first cytokine receptor-binding domain, VL1, and CH11 in sequence from the N-terminus to the C-terminus; and a third polypeptide containing a second cytokine receptor-binding domain, VH2, CH12, and a second Fc domain subunit in sequence from the N-terminus to the C-terminus.

[0198] In one aspect, the antigen-binding molecule comprises a first target-binding domain and a second target-binding domain that specifically bind to FAP, and the first and second cytokine receptor subunits are subunits of an IFNγ receptor complex. In another aspect, the antigen-binding molecule comprises a first target-binding domain and a second target-binding domain that specifically bind to FAP, and the first cytokine receptor binding domain is capable of binding IFNγR1 and the second cytokine receptor binding domain is capable of binding IFNγR2. In yet another aspect, the antigen-binding molecule comprises a first target-binding domain and a second target-binding domain that specifically bind to FAP, and the first cytokine receptor binding domain is capable of binding IFNγR2 and the second cytokine receptor binding domain is capable of binding IFNγR1.

[0199] In one aspect, the antigen-binding molecule comprises a first polypeptide containing, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VH1, and CH11; a second polypeptide containing, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VL1, and CL1; a third polypeptide containing, in sequence from the N-terminus to the C-terminus, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide containing, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VH2, and CL2, wherein VH1, VL1, CH11, and CL1 form a first target-binding domain, and VH2, VL2, CH12, and CL2 form a second target-binding domain, wherein the first and second target-binding domains bind FAP, and the first and second cytokine receptor-binding domains bind subunits of the IFNγ receptor complex.

[0200] In one aspect, the antigen-binding molecule comprises a first polypeptide (containing the first polypeptide) having a first Fc domain subunit, VL1, and CH11 in sequence from the N-terminus to the C-terminus; a second polypeptide having a first cytokine receptor-binding domain, VH1, and CL1 in sequence from the N-terminus to the C-terminus; a third polypeptide having VH2, CH12, and a second Fc domain subunit in sequence from the N-terminus to the C-terminus; and a fourth polypeptide having a second cytokine receptor-binding domain, VL2, and CL2 in sequence from the N-terminus to the C-terminus, wherein VH1, VL1, CH11, and CL1 form a first target-binding domain, and VH2, VL2, CH12, and CL2 form a second target-binding domain, wherein the first and second target-binding domains bind FAP, and the first and second cytokine receptor-binding domains bind subunits of the IFNγ receptor complex.

[0201] In one aspect, the antigen-binding molecule comprises a first polypeptide containing, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VL1, and CL1; a second polypeptide containing, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VH1, and CH11; a third polypeptide containing, in sequence from the N-terminus to the C-terminus, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide containing, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VH2, and CL2, wherein VH1, VL1, CH11, and CL1 form a first target-binding domain, and VH2, VL2, CH12, and CL2 form a second target-binding domain, wherein the first and second target-binding domains bind FAP, and the first and second cytokine receptor-binding domains bind subunits of the IFNγ receptor complex.

[0202] In one aspect, the antigen-binding molecule comprises a first polypeptide containing, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VH1, and CL1; a second polypeptide containing, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VL1, and CH11; a third polypeptide containing, in sequence from the N-terminus to the C-terminus, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide containing, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VL2, and CL2, wherein VH1, VL1, CH11, and CL1 form a first target-binding domain, and VH2, VL2, CH12, and CL2 form a second target-binding domain, wherein the first and second target-binding domains bind FAP, and the first and second cytokine receptor-binding domains bind subunits of the IFNγ receptor complex.

[0203] In one aspect, the antigen-binding molecule comprises a first polypeptide containing, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VH1, and CH11; a second polypeptide containing, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VL1, and CL1; a third polypeptide containing, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide containing, in sequence from the N-terminus to the C-terminus, VH2 and CL2, wherein VH1, VL1, CH11, and CL1 form a first target-binding domain, and VH2, VL2, CH12, and CL2 form a second target-binding domain, wherein the first and second target-binding domains bind FAP, and the first and second cytokine receptor-binding domains bind subunits of the IFNγ receptor complex.

[0204] In one aspect, the antigen-binding molecule comprises a first polypeptide containing, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VL1, and CH11; a second polypeptide containing, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VH1, and CL1; a third polypeptide containing, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide containing, in sequence from the N-terminus to the C-terminus, VL2 and CL2, wherein VH1, VL1, CH11, and CL1 form a first target-binding domain, and VH2, VL2, CH12, and CL2 form a second target-binding domain, wherein the first and second target-binding domains bind FAP, and the first and second cytokine receptor-binding domains bind subunits of the IFNγ receptor complex.

[0205] In one aspect, the antigen-binding molecule comprises a first polypeptide containing, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VL1, and CL1; a second polypeptide containing, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VH1, and CH11; a third polypeptide containing, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide containing, in sequence from the N-terminus to the C-terminus, VH2 and CL2, wherein VH1, VL1, CH11, and CL1 form a first target-binding domain, and VH2, VL2, CH12, and CL2 form a second target-binding domain, wherein the first and second target-binding domains bind FAP, and the first and second cytokine receptor-binding domains bind subunits of the IFNγ receptor complex.

[0206] In one aspect, the antigen-binding molecule comprises a first polypeptide containing, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VH1, and CL1; a second polypeptide containing, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VL1, and CH11; a third polypeptide containing, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide containing, in sequence from the N-terminus to the C-terminus, VL2 and CL2, wherein VH1, VL1, CH11, and CL1 form a first target-binding domain, and VH2, VL2, CH12, and CL2 form a second target-binding domain, wherein the first and second target-binding domains bind FAP, and the first and second cytokine receptor-binding domains bind subunits of the IFNγ receptor complex.

[0207] In one aspect, the antigen-binding molecule comprises a first target-binding domain and a second target-binding domain that specifically bind to PD-1, and the first and second cytokine receptor subunits are subunits of the IL-2 receptor complex. In another aspect, the antigen-binding molecule comprises a first target-binding domain and a second target-binding domain that specifically bind to FAP, and the first cytokine receptor binding domain is capable of binding IL-2Rβ and the second cytokine receptor binding domain is capable of binding IL-2Rγ. In yet another aspect, the antigen-binding molecule comprises a first target-binding domain and a second target-binding domain that specifically bind to FAP, and the first cytokine receptor binding domain is capable of binding IL-2Rγ and the second cytokine receptor binding domain is capable of binding IL-2Rβ.

[0208] In one aspect, the antigen-binding molecule comprises a first polypeptide containing, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VL1, and CL1; a second polypeptide containing, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VH1, and CH11; a third polypeptide containing, in sequence from the N-terminus to the C-terminus, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide containing, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VH2, and CL2, wherein VH1, VL1, CH11, and CL1 form a first target-binding domain, and VH2, VL2, CH12, and CL2 form a second target-binding domain, wherein the first and second target-binding domains bind PD-1, and the first and second cytokine receptor-binding domains bind subunits of the IL-2 receptor complex.

[0209] In one aspect, the antigen-binding molecule comprises a first polypeptide containing, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VH1, and CL1; a second polypeptide containing, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VL1, and CH11; a third polypeptide containing, in sequence from the N-terminus to the C-terminus, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide containing, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VL2, and CL2, wherein VH1, VL1, CH11, and CL1 form a first target-binding domain, and VH2, VL2, CH12, and CL2 form a second target-binding domain, wherein the first and second target-binding domains bind PD-1, and the first and second cytokine receptor-binding domains bind subunits of the IL-2 receptor complex.

[0210] In one aspect, the antigen-binding molecule comprises a first polypeptide containing, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VH1, and CH11; a second polypeptide containing, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VL1, and CL1; a third polypeptide containing, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide containing, in sequence from the N-terminus to the C-terminus, VH2 and CL2, wherein VH1, VL1, CH11, and CL1 form a first target-binding domain, and VH2, VL2, CH12, and CL2 form a second target-binding domain, wherein the first and second target-binding domains bind PD-1, and the first and second cytokine receptor-binding domains bind subunits of the IL-2 receptor complex.

[0211] In one aspect, the antigen-binding molecule comprises a first polypeptide containing, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VL1, and CH11; a second polypeptide containing, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VH1, and CL1; a third polypeptide containing, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide containing, in sequence from the N-terminus to the C-terminus, VL2 and CL2, wherein VH1, VL1, CH11, and CL1 form a first target-binding domain, and VH2, VL2, CH12, and CL2 form a second target-binding domain, wherein the first and second target-binding domains bind PD-1, and the first and second cytokine receptor-binding domains bind subunits of the IL-2 receptor complex.

[0212] In one aspect, the antigen-binding molecule comprises a first polypeptide containing, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VL1, and CL1; a second polypeptide containing, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VH1, and CH11; a third polypeptide containing, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide containing, in sequence from the N-terminus to the C-terminus, VH2 and CL2, wherein VH1, VL1, CH11, and CL1 form a first target-binding domain, and VH2, VL2, CH12, and CL2 form a second target-binding domain, wherein the first and second target-binding domains bind PD-1, and the first and second cytokine receptor-binding domains bind subunits of the IL-2 receptor complex.

[0213] In one aspect, the antigen-binding molecule comprises a first polypeptide containing, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VH1, and CL1; a second polypeptide containing, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VL1, and CH11; a third polypeptide containing, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide containing, in sequence from the N-terminus to the C-terminus, VL2 and CL2, wherein VH1, VL1, CH11, and CL1 form a first target-binding domain, and VH2, VL2, CH12, and CL2 form a second target-binding domain, wherein the first and second target-binding domains bind PD-1, and the first and second cytokine receptor-binding domains bind subunits of the IL-2 receptor complex.

[0214] The binding molecule's domains (target antigen-binding domain, cytokine receptor-binding domain, and Fc domain) can be fused together via one or more peptide linkers, particularly (G4S)n peptide linkers. The cytokine receptor-binding domain can be linked to the target antigen-binding domain via (G4S)1 peptide linker (GGGGS; SEQ ID NO: 118), (G4S)2 peptide linker (GGGGSGGGGS; SEQ ID NO: 119), (G4S)3 peptide linker (GGGGSGGGGSGGGGS; SEQ ID NO: 120), or (G4S)5 peptide linker (GGGGSGGGGSGGGGSGGGGS; SEQ ID NO: 121). The target-binding domain can be fused to the C-terminus of one of the Fc domain subunits at the N-terminus of its VH or VL via a (G4S)1 peptide linker, (G4S)2 peptide linker, (G4S)3 peptide linker, or (G4S)5 peptide linker.

[0215] In one aspect, the antigen-binding molecule comprises: a first polypeptide comprising the amino acid sequence of SEQ ID NO: 50; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 48; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 51; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 49. In another aspect, the antigen-binding molecule comprises: a first polypeptide comprising the amino acid sequence of SEQ ID NO: 99; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 97; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 100; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 98. In another aspect, the antigen-binding molecule comprises: a first polypeptide comprising the amino acid sequence of SEQ ID NO: 103; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 101; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 104; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 102. In one aspect, the antigen-binding molecule comprises: a first polypeptide comprising the amino acid sequence of SEQ ID NO: 107; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 105; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 108; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 106. In another aspect, the antigen-binding molecule comprises: a first polypeptide comprising the amino acid sequence of SEQ ID NO: 99; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 109; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 100; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 110. In another aspect, the antigen-binding molecule comprises: a first polypeptide comprising the amino acid sequence of SEQ ID NO: 107; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 111; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 113; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 112. In one aspect, the antigen-binding molecule comprises: a first polypeptide comprising the amino acid sequence of SEQ ID NO: 99; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 114; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 100; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 115.In one aspect, the antigen-binding molecule comprises: a first polypeptide comprising the amino acid sequence of SEQ ID NO: 107; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 116; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 108; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 117.

[0216] In one aspect, the antigen-binding molecule comprises: a first polypeptide comprising the amino acid sequence of SEQ ID NO: 123; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 122; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 124; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 125.

[0217] Specific embodiments of the present invention

[0218] Specific embodiments of the present invention are listed below.

[0219] 1. An antigen-binding molecule comprising

[0220] i) First target-binding structural domain

[0221] ii) Second target-binding structural domain,

[0222] iii) First cytokine receptor binding domain,

[0223] iv) Second cytokine receptor binding domain, and

[0224] v) Fc structural domain,

[0225] The first target-binding domain can bind to a first epitope on the target antigen, and the second target-binding domain can bind to a second epitope on the target antigen, wherein the first target-binding domain and the second target-binding domain do not compete for binding to the tumor-associated antigen; and

[0226] The first cytokine receptor binding domain can bind to the first cytokine receptor subunit, and the second cytokine receptor binding domain can bind to the second cytokine receptor subunit.

[0227] 2. The antigen-binding molecule according to Example 1, wherein the first binding domain and the second target binding domain are antibody fragments, particularly Fv, Fab, scFv, scFab or single-domain antibodies.

[0228] 3. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the first target-binding domain and the second target-binding domain are Fab molecules.

[0229] 4. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the first target-binding domain comprises a heavy chain variable domain (VH1), a light chain variable domain (VL1), a heavy chain constant domain (CH11), and a light chain constant domain (CL1), and the second target-binding domain comprises a heavy chain variable domain (VH2), a light chain variable domain (VL2), a heavy chain constant domain (CH12), and a light chain constant domain (CL2).

[0230] 5. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the first target-binding domain and / or the second target-binding domain are cross-Fab molecules.

[0231] 6. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the first target-binding domain and / or the second target-binding domain comprises a charge mutation.

[0232] 7. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the first target-binding domain is a cross-Fab and the second target-binding domain contains a charge mutation, or wherein the second target-binding domain is a cross-Fab and the first target-binding domain contains a charge mutation.

[0233] 8. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the first target-binding domain and the second target-binding domain specifically bind to tumor-associated antigens or T-cell antigens.

[0234] 9. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the first target-binding domain and the second target-binding domain specifically bind to FAP, PD-1, Her2, Her3, LAG-3, CEA, or EGFR.

[0235] 10. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the first target-binding domain and the second target-binding domain specifically bind FAP or PD-1.

[0236] 11. The antigen-binding molecule according to any one of the foregoing embodiments, wherein

[0237] a) The first target-binding domain comprises VH1 of SEQ ID NO: 20 and VL1 of SEQ ID NO: 21, and the second target-binding domain comprises VH2 of SEQ ID NO: 22 and VL2 of SEQ ID NO: 23, or

[0238] b) The first target-binding domain comprises VH1 of SEQ ID NO: 22 and VL1 of SEQ ID NO: 23, and the second target-binding domain comprises VH2 of SEQ ID NO: 20 and VL2 of SEQ ID NO: 21, or

[0239] c) The first target-binding domain comprises VH1 of SEQ ID NO: 80 and VL1 of SEQ ID NO: 81, and the second target-binding domain comprises VH2 of SEQ ID NO: 82 and VL2 of SEQ ID NO: 83, or

[0240] d) The first target-binding domain comprises VH1 of SEQ ID NO: 82 and VL1 of SEQ ID NO: 83, and the second target-binding domain comprises VH2 of SEQ ID NO: 80 and VL2 of SEQ ID NO: 81; or

[0241] e) The first target-binding domain comprises VH1 of SEQ ID NO: 82 and VL1 of SEQ ID NO: 83, and the second target-binding domain comprises VH2 of SEQ ID NO: 140 and VL2 of SEQ ID NO: 141; or

[0242] f) The first target-binding domain includes VH1 of SEQ ID NO: 140 and VL1 of SEQ ID NO: 141, and the second target-binding domain includes VH2 of SEQ ID NO: 82 and VL2 of SEQ ID NO: 83.

[0243] 12. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the first cytokine receptor subunit and the second cytokine receptor subunit are both subunits of the IFNγ receptor complex or the IL-2 receptor complex.

[0244] 13. The antigen-binding molecule according to any one of the foregoing embodiments, wherein

[0245] a) The first cytokine receptor binding domain can bind IFNγR1 and the second cytokine receptor binding domain can bind IFNγR2, or

[0246] b) The first cytokine receptor binding domain can bind IFNγR2 and the second cytokine receptor binding domain can bind IFNγR1;

[0247] c) The first cytokine receptor binding domain can bind IL-2Rβ and the second cytokine receptor binding domain can bind IL-2Rγ; or

[0248] d) The first cytokine receptor binding domain can bind IL-2Rγ and the second cytokine receptor binding domain can bind IL-2Rβ.

[0249] 14. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the first cytokine receptor binding domain and the second cytokine receptor binding domain are antibody fragments, particularly Fv, Fab, scFv, scFab, single-domain antibodies, or VHH domains.

[0250] 15. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the first cytokine receptor binding domain and the second cytokine receptor binding domain are VHH domains.

[0251] 16. The antigen-binding molecule according to any one of the foregoing embodiments, wherein

[0252] a) The first cytokine receptor binding domain comprises an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 5, and the second cytokine receptor binding domain comprises an amino acid sequence selected from SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 9, or

[0253] b) The first cytokine receptor binding domain comprises an amino acid sequence selected from SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 9, and the second cytokine receptor binding domain comprises an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 5; or

[0254] c) The first cytokine receptor binding domain comprises the sequences of SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, and SEQ ID NO: 64, and the second cytokine receptor binding domain comprises the sequences of SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or

[0255] d) The first cytokine receptor binding domain comprises the sequences of SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68 and SEQ ID NO: 69, and the second cytokine receptor binding domain comprises the sequences of SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62 and SEQ ID NO: 64.

[0256] 17. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the Fc domain comprises a first Fc domain subunit and a second Fc domain subunit.

[0257] 18. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the Fc domain is an IgGFc domain, particularly an IgG1 Fc domain.

[0258] 19. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the Fc domain is a human Fc domain.

[0259] 20. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the Fc domain comprises modifications that promote association between a first subunit and a second subunit of the Fc domain.

[0260] 21. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the Fc domain comprises one or more amino acid substitutions that reduce binding to the Fc receptor and / or effector function.

[0261] 22. The antigen-binding molecule according to any one of the foregoing embodiments, wherein

[0262] The first cytokine receptor binding domain fuses at its C-terminus to the N-terminus of the first target binding domain VH1 or VL1, and the first target binding domain fuses at the N-terminus of the first Fc domain subunit to the C-terminus of the first Fc domain subunit. The second cytokine receptor binding domain fuses at its C-terminus to the N-terminus of the second target binding domain VH2 or VL2, and the second target binding domain fuses at the C-terminus of the second Fc domain subunit to the N-terminus of the second CH12 or CL1 domain.

[0263] 23. The antigen-binding molecule according to any one of the foregoing embodiments, comprising:

[0264] a) A first polypeptide comprising, in sequence from N-terminus to C-terminus, a first Fc domain subunit, VH1, and CH11; a second polypeptide comprising, in sequence from N-terminus to C-terminus, a first cytokine receptor-binding domain, VL1, and CL1; a third polypeptide comprising, in sequence from N-terminus to C-terminus, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from N-terminus to C-terminus, a second cytokine receptor-binding domain, VH2, and CL2; or

[0265] b) A first polypeptide comprising, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VL1, and CH11; a second polypeptide comprising, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VH1, and CL1; a third polypeptide comprising, in sequence from the N-terminus to the C-terminus, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VL2, and CL2; or

[0266] c) A first polypeptide comprising, in sequence from N-terminus to C-terminus, a first Fc domain subunit, VL1, and CL1; a second polypeptide comprising, in sequence from N-terminus to C-terminus, a first cytokine receptor-binding domain, VH1, and CH11; a third polypeptide comprising, in sequence from N-terminus to C-terminus, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from N-terminus to C-terminus, a second cytokine receptor-binding domain, VH2, and CL2; or

[0267] d) A first polypeptide comprising, in sequence from N-terminus to C-terminus, a first Fc domain subunit, VH1, and CL1; a second polypeptide comprising, in sequence from N-terminus to C-terminus, a first cytokine receptor-binding domain, VL1, and CH11; a third polypeptide comprising, in sequence from N-terminus to C-terminus, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from N-terminus to C-terminus, a second cytokine receptor-binding domain, VL2, and CL2; or

[0268] e) A first polypeptide comprising, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VH1, and CH11; a second polypeptide comprising, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VL1, and CL1; a third polypeptide comprising, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from the N-terminus to the C-terminus, VH2 and CL2; or

[0269] f) A first polypeptide comprising, in sequence from N-terminus to C-terminus, a first Fc domain subunit, VL1, and CH11; a second polypeptide comprising, in sequence from N-terminus to C-terminus, a first cytokine receptor-binding domain, VH1, and CL1; a third polypeptide comprising, in sequence from N-terminus to C-terminus, a second cytokine receptor-binding domain, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from N-terminus to C-terminus, VL2 and CL2; or

[0270] g) A first polypeptide comprising, in sequence from N-terminus to C-terminus, a first Fc domain subunit, VL1, and CL1; a second polypeptide comprising, in sequence from N-terminus to C-terminus, a first cytokine receptor-binding domain, VH1, and CH11; a third polypeptide comprising, in sequence from N-terminus to C-terminus, a second cytokine receptor-binding domain, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from N-terminus to C-terminus, VH2 and CL2; or

[0271] h) A first polypeptide comprising, in order from N-terminus to C-terminus, a first Fc domain subunit, VH1, and CL1; a second polypeptide comprising, in order from N-terminus to C-terminus, a first cytokine receptor binding domain, VL1, and CH11; a third polypeptide comprising, in order from N-terminus to C-terminus, a second cytokine receptor binding domain, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in order from N-terminus to C-terminus, VL2 and CL2.

[0272] VH1, VL1, CH11, and CL1 form the first target-binding domain, and VH2, VL2, CH12, and CL2 form the second target-binding domain.

[0273] 24. The antigen-binding molecule according to any one of the foregoing embodiments, wherein the first target-binding domain and the second target-binding domain specifically bind FAP, and the first cytokine receptor subunit and the second cytokine receptor subunit are subunits of the IFNγ receptor complex.

[0274] 25. The antigen-binding molecule according to any one of the foregoing embodiments, comprising:

[0275] a) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 50; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 48; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 51; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 49;

[0276] b) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 99; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 97; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 100; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 98;

[0277] c) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 103; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 101; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 104; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 102.

[0278] d) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 107; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 105; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 108; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 106;

[0279] e) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 99; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 109; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 100; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 110:

[0280] f) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 107; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 111; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 113; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 112.

[0281] g) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 99; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 114; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 100; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 115.

[0282] h) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 107; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 116; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 108; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 117.

[0283] 26. The antigen-binding molecule according to any one of Examples 1 to 23, wherein the first target-binding domain and the second target-binding domain specifically bind PD-1, and the first cytokine receptor subunit and the second cytokine receptor subunit are subunits of the IL-2 receptor complex.

[0284] 27. The antigen-binding molecule according to Example 25, comprising a first polypeptide comprising the amino acid sequence of SEQ ID NO: 123; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 122; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 124; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 125.

[0285] Example

[0286] Example 1: Production of binders to cytokine receptor subunits

[0287] 1.1 Generation of antigens used for immunization and phage display

[0288] For llama immunization, the extracellular domain (ECD) of the human IFNγR1 subunit and the ECD of the human IFNγR2 subunit were co-expressed as Fc-labeled heterodimers using a mortar and pestle technique (Fig. 1A, P1AG0843). Similarly, the ECDs of the human IL-2Rβ (CD122) subunit and the human IL-2Rγ (common γ chain; CD132) subunit were co-expressed as Fc-labeled heterodimers (Fig. 1D, P1AE2657). The C-terminus of the IFNγR1 ECD was fused to the Fc mortar via a G4SG4 l linker. During co-expression with BirA biotinylate ligase, an AviTag was included at the C-terminus of the Fc for site-specific biotinylation. The IFNγR2 ECD containing a C174S substitution was fused to the Fc mortar via a G4SG4 linker, and the construct contained a C-terminal Twin-Strep tag. The C-terminus of IL-2Rβ ECD is fused to the Fc ligand via a GAQ linker. During co-expression with BirA biotinylate ligase, an AviTag is included at the C-terminus of Fc for site-specific biotinylation. IL-2Rγ ECD is fused to the C-terminus of Fc ligand using a GAQ linker.

[0289] For phage display, monovalent IFNγR1ECD fused with a biotinylated Fc mortar (paired with an empty Fc mortar) was generated (Fig. 1B, P1AG1987), and monovalent IFNγR2 ECDC174S fused with an Fc mortar (paired with an empty biotinylated Fc mortar) was generated (Fig. 1C, P1AG6735). Additionally, monovalent IL-2RβECD fused with a biotinylated Fc mortar (paired with an empty Fc mortar) was generated (Fig. 1E, P1AF1104), and monovalent IL-2Rγ ECD fused with an Fc mortar (paired with an empty biotinylated Fc mortar) was generated (Fig. 1F, P1AF1106). All antigens were generated using the Expi293 mammalian expression system (Expi293™ ExpressionSystem Kit, Thermo Fisher Scientific, catalog number: A14635). As recommended by the manufacturer, the supernatant was collected by centrifugation and subjected to protein A affinity chromatography (Protein A MabSelect). TM Sure TM (Cytiva, catalog number: 17543803) Filtered and purified, then subjected to size exclusion chromatography (SEC) (HiLoad S200 16 / 600, Cytiva, catalog number: 28989335).

[0290] 1.2 VHH Library Construction

[0291] VHH Library, used by ProSci Inc., contains approximately ~3x10 from Bleeding 2. 8 Peripheral blood mononuclear cells (PBMCs) and ~6.6 x 10⁻³ cells from a single llama hemorrhage. 8 PBMC construction. This library was provided in E. coli strain TG1 encoding a derivative of the pADL-23c phage vector (Antibody Design Labs, San Diego, CA), using approximately ~1x10⁻⁶ phage vectors. 9 Independent electroporation events with >95% insertion efficiency were incorporated. In 2xYT medium containing 20% ​​glycerol, at a concentration of ~3.2x10⁻⁶. 10 The library was provided in the form of cfu / mL E. coli.

[0292] 1.3 Generation of VHH phage library

[0293] *E. coli* containing a phage particle library encoded by VHH were inoculated into 2xYT medium containing 100 µg / ml ampicillin and 1% glucose. After infection with VCSM13 helper phage, *E. coli* were grown in 2xYT medium containing 100 µg / ml ampicillin and 50 µg / ml kanamycin. After incubation overnight at 30°C on a shaker, the culture was harvested by centrifugation at 8000 rpm for 20 min, and the supernatant was collected. The phage was precipitated in 20% PEG / 2.5 M NaCl solution and incubated on ice for 1 h. The precipitated phage was centrifuged at 8000 rpm for 20 min, and the particles were resuspended in ddH2O, followed by precipitation in PEG / NaCl solution on ice for 1 h. The phages were centrifuged at 8000 rpm for 20 minutes and the particles were resuspended in PBS containing 20% ​​glycerol.

[0294] 1.4 Phage display was used to isolate IFNγR1-specific, IFNγR2-specific, and IL-2Rβ-specific antibodies. IL-2Rγ specific VHH

[0295] To selectively enrich antigen-specific binders and prevent the enrichment of Fc-specific binders, competitive solubility selection was performed against human IFNγR1 antigen (P1AG1987), human IFNγR2 antigen (P1AG6735), human IL-2Rβ antigen (P1AF1104), and human IL-2Rγ antigen (P1AF1106) in the presence of human Fc (Fig. 1G, P1AD4290). Each antigen was selected using 1x10⁻¹⁰ samples from a llama-derived VHH library. 11Aliquots of phages were prepared. Phages and magnetic streptavidin beads (Dynabeads; M-280 streptavidin, Invitrogen, catalog number: 11205D) were independently blocked in phosphate-buffered saline (PBS) with 1% BSA and 0.1% Tween-20 to reduce nonspecific interactions. All cultures were incubated at 20°C for one hour unless otherwise specified. Biotinylated Fc-labeled antigen was added to the blocked phages at a concentration of 100 nM in the presence of excess (500 nM) of non-biotinylated Fc (Figure 2). After incubation, pre-blocked Dynabeads were added to capture the target biotinylated antigen and bind VHH-expressing phages. Fc-specific and non-specific phages were removed by 5 to 10 washes in PBS containing 0.1% Tween-20, followed by PBS removal using a KingFisher magnetic particle processor (Thermo Fisher Scientific). Antigen-specific phages were eluted in 800 µl of 100 mM trimethylamine (TEA) and neutralized by adding 400 µl of 1 M Tris at pH 7.4. The eluted phages were used to infect intermediate-log phase TG1 *E. coli* in 2xYT medium, followed by VCSM13 helper phage infection. Infected *E. coli* were incubated overnight at 30°C on a shaker after adding 100 µg / ml ampicillin and 50 µg / ml kanamycin. The phages were precipitated with PEG / NaCl and used for the next round. A total of three rounds of selection were performed using reduced target antigen concentrations (100 nM, 50 nM, 25 nM), while the soluble Fc concentration remained constant (500 nM) (Figure 2).

[0296] 1.5 Validate target specificity using ELISA

[0297] The target specificity and Fc specificity of the third-round enrichment library were screened by ELISA. A single VHH clone was expressed in 1 ml of *E. coli* culture in 96-well plates, and the specificity of the supernatant containing soluble VHH was screened by ELISA. The supernatant was transferred to a 96-well plate coated with a neutral avidin-coated Fc (P1AE6073) or a biotinylated antigen labeled with the target Fc (P1AG1987, P1AG6735, P1AF1104, or P1AF1106). After incubation at 20°C for 1 hour, the plate was washed three times with PBST and three times with PBS. HRP-conjugated anti-His antibody (Sigma, catalog number: A7058) was added to the wells at a dilution of 1:2000, and the plate was incubated at room temperature for 1 hour. The plate was washed three times with PBST and then three times with PBS. The plate was developed by adding a 1-step Ultra TMB-ELISA substrate (Thermo Fisher Scientific, catalog number: 34028), and the reaction was quenched with sulfuric acid. Absorbance was measured at 450 nm using a Tecan Infinite M1000 Pro, and a reference absorbance value was measured at 650 nm. The reference-subtracted absorbance values ​​at 450 nm were represented as a stacked bar graph of IFNγR1-specific VHH (Figure 3A), IFNγR2-specific VHH (Figure 3B), IL-2Rβ-specific VHH (Figure 3C), and IL-2Rγ-specific VHH (Figure 3D). ELISA data showed that >90% of the clones were target-specific, and VHHs from the third-round enrichment library were subsequently cloned into a bispecific heavy chain antibody format.

[0298] Example 2: Evaluation of agonist activity against IFNγ and IL-2 receptors

[0299] 2.1 The enriched VHH library was assembled into a heavy chain antibody format.

[0300] IFNγR activation is achieved through IFNγ-mediated crosslinking of the IFNγR1 and IFNγR2 receptor chains. To mimic assembly in an IFNγ-independent manner, the IFNγR1-specific VHH domain is paired with the IFNγR2-specific VHH domain via fusion of a flexible linker generating an IFNγR1-IFNγR2 bispecific heavy chain antibody with the mordant Fc chain. IL-2R activation is achieved through IL-2Rβ and IL-2Rγ receptor chains mediated by IL-2. Therefore, to mimic assembly in an IL-2-independent manner, the IL-2Rβ-specific VHH domain is paired with the IL-2Rγ-specific VHH domain via fusion of a flexible linker generating an IL-2Rβ-IL-2Rγ bispecific heavy chain antibody with the mordant Fc chain. To this end, Gibson assembly was used to assemble batch clones enriched with IFNγR1 or IL-2Rβ-specific third-round VHH libraries for VHH format conversion via fusion with Fc clathrin via 5(G4S) adapters (Figure 4A). Similarly, third-round IFNγR2 or IL-2Rγ-specific VHH libraries were assembled using Gibson assembly via fusion with Fc clathrin via 5(G4S) adapters (Figure 4B). Suitable signal sequences and mammalian expression-compatible vectors were included during assembly. Primers, PCR conditions, and Gibson assembly reactions were defined according to the New England Biolabs NEBuilder HiFi DNA Assembly Protocol (catalog number: E5510). After bacterial transformation, colonies were randomly selected, and five unique sequences were chosen from each specific pool. Using the Expi293 system, 5x5 matrices were generated to express 25 unique mortar-and-pot bispecific heavy chain antibodies containing IFNγR1 and IFNγR2 VHH pairs and 25 unique mortar-and-pot bispecific heavy chain antibodies containing IL-2Rβ VHH and IL-2Rγ VHH pairs (Figure 5). Expi293 cells were transiently transfected according to the manufacturer's recommendations (Expi293™ Expression System Kit, Thermo Fisher Scientific, catalog number: A14635), and supernatants containing secreted soluble bispecific heavy chain antibodies were collected. The bispecific heavy chain antibodies were purified by protein A resin, and their functional activity was further characterized using reporter cell assays.

[0301] 2.2 Functional characterization of bispecific heavy chain antibodies

[0302] The HEK Blue IFNγ reporter cell assay (Invivogen) was used to screen for bispecific heavy chain antibodies containing different IFNγR1 and IFNγR2 VHH pairs and to identify IFNγR agonists. Conversely, the HEK Blue IL-2 reporter cell assay (Invivogen) was used to screen for bispecific heavy chain antibodies containing different IL-2Rβ and IL-2Rγ VHH pairs and to identify IL-2R agonists. The in vitro HEK Blue IFNγ reporter cell system (Invivogen, catalog number: hkb-ifng) reports IFNγR signaling via a STAT1-induced secretory alkaline phosphatase (SEAP) system. In vitro HEK blue IL-2 reporter cells (Invivogen, catalog number: hkb-il2) reconstructed the human IL-2R signaling pathway via expression of the IL-2R chain (IL-2Rα, β, and γ subunits) and downstream signaling cascade effectors (JAK3 and STAT5), as well as the STAT5-induced secretory alkaline phosphatase (SEAP) reporter system. Absorbance at 650 nm was measured on QuantiBlue substrate (Invivogen, catalog number: rep-qbs) and correlated with SEAP levels and IFNγR and IL-2R activities, respectively. In the initial screening, supernatant from Expi293 5x5 expression matrices containing soluble IFNγR1-IFNγR2 or IL-2Rβ-IL-2Rγ bispecific heavy chain antibodies was incubated with HEK blue IFNγ or HEK blue IL-2 reporter cells, respectively. After 20 hours of incubation, the activities of IFNγR and IL-2 were quantified by adding QuantiBlue reagent (Invivogen, catalog number: rep-qbs) according to the manufacturer's recommendations. Absorbance was measured at 650 nm, with higher absorbance levels indicating increased IFNγR or IL-2 signaling.

[0303] Of the 25 tested IFNγR1-IFNγR2 bispecific heavy chain antibodies (format depicted in Figure 5), 14 showed IFNγR activity (Figure 6A). Therefore, 14 pairs of IFNγR1- and IFNγR2-VHH domains exhibited IFNγ agonist activity. Of the 25 tested IL-2Rβ-IL-2Rγ bispecific heavy chain antibodies, 9 pairs containing nonspecific VHH domains (IL2Rβ_4 and IL2Rγ_1) did not induce IL-2R activity. The other 16 pairs, formed by functional IL-2Rβ and IL-2Rγ binders, all exhibited IL-2R agonist activity (Figure 6B). Therefore, 16 pairs of IL-2Rβ- and IL-2Rγ-VHH domains exhibited IL-2 agonist activity.

[0304] Next, the dose-dependent IFNγR signaling of the purified agonist IFNγR1-IFNγR2 bispecific heavy chain antibody (P1AH1877-P1AH1890, see Table 1) was tested, as well as the dose-dependent IL-2R signaling of the agonist IL-2Rβ-IL-2Rγ bispecific heavy chain antibody (see Table 2).

[0305] Table 1: IFNγR1-IFNγR2 bispecific heavy chain antibodies generated from the 5x5 expression matrix showing IFNγ agonist activity in Figure 6A.

[0306]

[0307] Following the Invivogen HEK Blue protocol, concentrations ranging from 100 nM to 0.01 nM with HEK Blue IFNγ cells were used. Absorbance was measured at 650 nm, and reaction plots were generated using GraphPad software (Figure 7). The plots were separated based on VHH clones specific to IFNγR1, with recombinant human IFNγ (recIFNγ; SEQ ID NO: 26) and anti-FAP IgG fused to IFNγ homodimers (P1AF3574; SEQ ID NO: 24 and SEQ ID NO: 25) serving as reference molecules. The various reactions observed in all plots, from potent IFNγ mimics to weak agonists, demonstrated the interaction between IFNγR1 and IFNγR2 binders. EC50 values ​​obtained using GraphPad Prism software (Figure 8) illustrate the breadth of agonistic activity and highlight the potential of VHH for achieving potent yet tunable cytokine mimics.

[0308] Table 2: IL-2Rβ-IL-2Rγ bispecific heavy chain antibodies generated from the 5x5 expression matrix showing IL-2R activity in Figure 6B.

[0309]

[0310] Following the Invivogen HEK Blue protocol, concentration ranges of 20 nM, 0.8 nM, and 0.032 nM were used with HEK Blue IL-2 reporter cells. The agonistic activity of the IL-2 mimic was compared with that of IL-2v fused with anti-PD1 IgG (PD1-IL2v; P1AE4422). VHH exhibited potent IL-2R agonism in a dose-dependent manner (Figure 9). Furthermore, in contrast to the activation of native cytokines mediated by a single molecule, the use of VHH to activate receptors via a molecular splitting approach provides an opportunity for conditionally active IL-2 mimics.

[0311] To further characterize the agonistic activity of the 14 functional IFNγR1- and IFNγR2-VHH pairs, various previously identified IFNγ-responsive tumor cell lines (MKN45, BxPC-3, COR-L105; data not shown) were selected to explore therapeutically relevant downstream effects of IFNγR signaling that may have the ability to modulate the tumor microenvironment (TME). In one case, MHC-I and PD-L1 were selected as tumor cell surface biomarkers to characterize the TME-modulating potential of the functional bispecific VHH pairs. MHC-I was upregulated as a downstream response to IFNγR stimulation and may increase antigenicity on tumor cells, while PD-L1 was upregulated as another downstream indicator of functional IFNγ signaling. To assess the ability of VHH to induce IFNγ signaling in vitro, tumor cells were incubated with 14 previously tested heavy chain antibodies (P1AH1877–P1AH1890) at concentrations ranging from 100 nM to 0.1 nM. After 72 hours, MHC-I and PD-L1 expression levels were quantified by flow cytometry, and data were analyzed using FlowJo software. Mean fluorescence intensity (MFI) values ​​were subtracted from blank and normalized to recombinant IFNγ responses. Upregulation of MHC-I and PD-L1 was measured in three tumor cell types: MKN45 (Fig. 10A, 10B), BxPC-3 (Fig. 10C, 10D), and COR-L105 (Fig. 10E, 10F). A variety of responses were observed, confirming the broad agonistic activity previously observed in HEK blue IFNγ reporter cells. One notable observation is that PD-L1 expression is generally reduced compared to MHC-I expression induced by certain VHH pairs, suggesting the complexity of IFNγ signaling, which may involve different pathways, and highlighting the possibility that agonistic VHH pairs can induce the phenotypic effects required to induce bias.

[0312] The induction of IFNγR signaling via agonist IFNγR VHH and the induction of IL-2R signaling via agonist IL-2R VHH provide opportunities for the engineering of conditionally active IFNγ and IL-2 mimics. As a starting point for conditional IFNγR agonists, P1AH1884 was chosen as a potent IFNγ mimic (Figure 8), whose activity closely correlated with recombinant IFNγ responses in all tested tumor lines (Figure 9). For conditional IL-2R agonists, P1AH1177 was chosen.

[0313] The corresponding VHH pairs were further engineered to produce conditionally active agonists.

[0314] Example 3: Engineering of conditionally active IFNγ and IL-2 mimics

[0315] 3.1 FAP-dependent dual complementary site assembly of split dual-targeted IFNγ mimics

[0316] To achieve conditional immunomodulation in the immune-abandoned tumor microenvironment, cell surface markers reportedly expressed in non-inflammatory tumor phenotypes were further explored. Fibroblast activation protein (FAP) (a serine protease described as being highly expressed in cancer-associated stromal tissue of immune-abandoned tumors) was selected as a target for achieving cold tumor penetration. As a next step, a pair of IFNγ-mimicking agonistic VHH domains were distributed on two separate molecules to inactivate the VHH pair, while simultaneously employing a FAP-dependent assembly strategy to restore agonistic VHH activity in the presence of FAP (Figure 11A). For this purpose, two proximal epitopes on the FAP antigen were selected, and corresponding non-competitive anti-FAP binders were engineered to mediate the assembly of the agonistic VHH pair. In the first case, the VHH domain of the P1AH1884 heavy chain antibody is fused to the N-terminus of the VH or VL domain of the anti-FAP binder via a flexible 5 (G4S) linker, resulting in eight possible conformations (Figure 11B-I). To test FAP-dependent IFNγR signaling, the upregulation of MHC-I and PD-L1 was quantified in three FAP expression protocols. First, non-targeted, FAP-independent activity was tested in a FAP-negative setting using the A549 lung adenocarcinoma cell line. Next, cis-FAP-dependent activity was characterized using A549 cells engineered for ectopic FAP expression, while FAP-positive and FAP-negative cell lines were differentially labeled and co-cultured to compare the cis and trans activities of the FAP-dependent IFNγ mimic. Divided dual-targeting IFNγ mimics were serially diluted across a concentration range of 10 nM to 1 pM. The recombinant IFNγ and the intact parental VHH pair lacking FAP targeting (P1AH1884, format shown in Figure 5) were used as reference molecules. After 72 h of incubation in three FAP expression scenarios, MHC-I and PD-L1 expression levels were quantified by flow cytometry. In the absence of FAP expression, upregulation of MHC-I and PD-L1 was induced by the reference molecule, while neither combination of split dual-targeting molecules showed FAP-independent activity (Figures 12A and 12B). In the presence of FAP expression, both the recapitulation of the cis-set (Figures 12C and 12D) and the recapitulation of the trans-set (Figures 12E and 12F) showed FAP-specific activity. In particular, the cis-set highlighted the importance of geometry for achieving potent activity, where a small format adjustment (i.e., exchanging the fusion site from VH to VL on the anti-FAP binder) translates into a major difference in IFNγR signaling.P1AI0831 + P1AI0066 provide the most potent FAP-dependent IFNγR activity. Interestingly, in the inverse scenario, geometric constraints do not apply to the same degree, where all format combinations exhibit FAP-dependent activity.

[0317] To further explore format options and expand our understanding of constraints imposed by molecular geometry, we designed additional molecular sets where VHH is further removed from the FAP-binding domain. VHH was fused to the N-terminus of the opposing Fc chain via a 3(G4S) linker (Fig. 13A-D) or to the C-terminus of the same Fc chain via a 3(G4S) linker (Fig. 13E-H). As previously described, these sets were tested in vitro in three FAP expression scenarios. FAP-independent activity was observed with reference molecules (recombinant IFNγ and P1AH1884, Fig. 14A and 14B), while the split dual-targeting combinations showed no IFNγR activation except for one combination at high concentrations (P1AI5306 + P1AI5307; Fig. 14A). Next, FAP-dependent activity (cis-targeting) was tested in FAP-expressing cells. Upregulation of MHC-I (Fig. 14C) and PD-L1 (Fig. 14D) was observed with the reference molecule and the P1AI5306 + P1AI5307 combination, but all other combinations remained inactive. Finally, the combinations were tested in the trans scenario to assess activity on FAP-negative cells in the presence of FAP-expressing cells. All combinations showed FAP-dependent trans activity, inducing upregulation of MHC-1 (Fig. 14E) and PD-L1 (Fig. 14F). By disconnecting the VHH-FAP binding moiety, FAP-dependent cis activity was rarely observed due to the previously identified geometric constraints imposed in the cis scenario. However, in the trans setting, all combinations showed IFNγR activation regardless of the formulation.

[0318] 3.2 Design of PD1-dependent double complementary bit combinations for IL-2 emulators

[0319] To maintain conditional agonistic activity while binding to tumor selectivity, a strategy was designed to leverage cell surface markers reportedly enriched in the tumor environment to support the assembly of IL-2 agonistic VHH domain pairs. The aim was to bind two proximal epitopes on a single target using two non-competitive anti-target binders (Fig. 15A). In the first case, PD-1 was chosen as the target for several reasons. First, PD-1 upregulation is observed during T cell activation, providing an opportunity to enhance selectivity for tumor-specific effector T cell populations. Second, a PD-L1 competitive anti-PD-1 binder would provide immune checkpoint inhibition mediated by blocking the PD1 / PD-L1 signaling cascade. Third, recent evidence highlights the synergistic effect of IL-2R agonism combined with cis-targeted PD-1 blocking, leading to differentiation of “better effector” T cells (Codarri Deak et al., Nature 610;161–172 (2022)).

[0320] In this experiment, based on IL-2R signaling using two pairs of IL-2 mimics (Figs. 15B and 15C) and PD1-IL2v (Fig. 15E, P1AE4422) as a reference molecule and a potent IL-2 agonist heavy chain antibody (Fig. 15D, P1AH117), activated PD-1 was treated with increased molecular concentrations. + and PD-1 - (Anti-PD1 pretreated) CD4 T cells were used to measure their potency and cis-delivery. The aim was to determine the dependence of PD-1-based IL-2R agonists on PD1 expression in T cells for delivery of IL-2R signaling.

[0321] For this purpose, CD4 T cells were sorted from healthy donor PBMCs using CD4 beads (Miltenyi, catalog number: 130-045-101) and activated for 3 days in the presence of 1 μg / ml plate-bound anti-CD3 (overnight pre-coated, clone OKT3, catalog number: 317315, BioLegend) and 1 μg / ml soluble anti-CD28 (clone CD28.2, catalog number: 302923, BioLegend) antibody to induce PD1 expression. After three days, cells were collected and washed several times to remove endogenous cytokines, with half of the cells labeled with CTV (5 μM, at 20°C for 5 min; catalog number: C34557, Thermo Scientific), while the other half were unlabeled.

[0322] Next, unlabeled cells were incubated with a saturated concentration of competitive anti-PD-1 antibody (internal molecule, 10 µg / ml) at 20°C for 30 min, followed by several washing steps to remove excess unbound anti-PD-1 antibody. Subsequently, PD-1 pre-blocked unlabeled cells (25 µl, 6*10⁶ cells) were... 6 (cells / ml) and PD1 + CTV-labeled cells (25 µl, 6 x 10⁻⁶) 6 Cells were co-cultured 1:1 in V-plates with a concentration of therapeutic molecule (50 µl, 1:10 dilution) at 37°C for 15 or 60 min. To maintain phosphorylation, an equal volume of Phosphoflow Fixation Buffer I (100 µl, catalog number: 557870, BD) was added after incubation with the various therapeutic molecules. Cells were then incubated at 37°C for another 30 min, followed by permeabilization overnight at -80°C with Phosphoflow PermBuffer III (catalog number: 558050, BD). The next day, phosphorylated STAT-5 was stained at 4°C for 30 min with anti-STAT-5P antibody (47 / Stat5(pY694) clone, catalog number: 562076, BD).

[0323] These cells were obtained at FACS BD-LSR Fortessa (BD Bioscience). The frequency of STAT-5P was determined using FlowJo (V10) and plotted using GraphPad Prism.

[0324] PD-1 +Dose-response profiles on T cells provide information on the efficacy of PD1-based IL-2R agonists in IL-2R signaling. Furthermore, dose-response profiles on T cells pretreated with a competitive anti-PD1 antibody to prevent PD1-mediated delivery show the efficacy of PD1-based IL-2R agonist molecules in providing IL-2R signaling independently of PD1 expression. PD1-IL2v showed reduced T cell activity in the absence of PD1 binding (pre-blocking) (Fig. 16, black solid and black dashed lines). Simultaneously, no activity was observed in the absence of PD1 binding for either combination of cleaved IL-2 mimics (P1AH6850 + P1AH6813, P1AH6814 + P1AI1593) (Fig. 16, light gray dashed line). No reduction in IL-2 signaling was observed with the non-targeting IL-2 agonist bispecific heavy chain antibody (P1AH1177, Figure 16, dark gray solid and dark gray dashed lines).

[0325] The concept of dual complementary site assembly was further investigated using alternative anti-PD-1 Fab binders (Figure 17). IL-2 signaling was assessed using HEK blue IL-2 wt cells (PD-1 negative) and HEK blue IL-2 cells expressing human PD-1.

[0326] As observed with the previously described PD-1-targeting IL-2R agonists (P1AH6814 + P1AI1593 and P1AH6850 + P1AH6813), no tested combination showed IL-2R signaling in the absence of PD-1 expression (Fig. 18A), while replacing the PD-1 binder 0376 with 7G12 (P1AK2802 + P1AK2599) also showed potent efficacy against PD-1-expressing cells (Fig. 18B). Of the eight tested PD-1-targeting IL-2R agonists containing the same group of PD-1 binders (7G12 and 1040), three showed strong dose-responsive IL-2R activation.

[0327] 3.3 FAP-dependent bicomponent site assembly using IFNγ mimics in single-molecule format

[0328] To determine whether a single molecule could retain all the features of a bimolecular approach that combines splitting molecules, we designed a four-specificity format that combines the requirements of a bimolecularly targeting molecule. The integrated format provides bicomponent assembly of cytokine receptors by merging two functionally splitting bicomponent molecules into one, thereby activating the VHH domain pair. First, the most potent splitting conformation of the IFNγ agonist was selected, demonstrating its ability to simultaneously provide cis and trans activity (P1AI0831 + P1AI0066; Fig. 12). Next, the two selected VHH-Fab fusions were grafted onto a single molecule, utilizing Fc as a spacer region to distance the VHH domains in a FAP-independent manner and reduce the likelihood of VHH-mediated IFNγR activation. Finally, a mortar and cross-Fab technique was combined to generate the four-specificity format while retaining the optimal fusion conformation defined in the P1AI0831 + P1AI0066 combination (Fig. 19). Specifically, a 5(G4S) joint is used to fuse the IFNγR1-specific VHH domain with the N-terminus of the anti-FAP binder 1 VL domain. The N-terminus of the anti-FAP binder 1 VH domain is fused to the C-terminus of the Fc pestle chain via a 3(G4S) joint, and the CH1 / CL domain is modified to include additional attracting charges. The anti-FAP binder 2 is located upstream of the hinge on the mortar chain and contains crossed VH / VL domains. A 5(G4S) joint is used to fuse the IFNγR2-specific VHH domain with the N-terminus of the VH domain now located on the light chain.

[0329] FAP-specific IFNγR activation was tested in vitro using the integrated formulation (designated P1AI5012) obtained using the three previously described FAP expression scenarios. In the absence of FAP expression, the reference molecule showed upregulation of MHC-I (Fig. 20A, dashed line) and PD-L1 (Fig. 20B, dashed line), while P1AI5012 did not induce IFNγR activation (Fig. 20A and 20B, solid lines). In FAP-expressing cells, P1AI5012 exhibited FAP-dependent IFNγR agonism, demonstrating activity similar to recombinant IFNγ at a low concentration of 25 pM (Fig. 20C and 20D). In the setting reproducing trans-activity, potent IFNγR agonism was observed in the presence of P1AI5012 (Fig. 20E and 20F).

[0330] 3.4 Additional format of "integrated" molecules

[0331] To determine whether the mechanism of action is inherent to the specific format produced, we designed several variants of the integrated format (P1AI5012) that differed in the agonist VHH pairs (VHH pair 1: IFNγR1_3 VHH and IFNγR2_2, derived from P1AH1884; VHH pair 2: IFNγR1_5 VHH and IFNγR2_1 VHH, derived from P1AH1886), the position of VHH on the VH or VL of the Fab domain, the different positions of the FAP binder, and the linker length between the Fab domain and the VHH (5, 10, 15, and 25 amino acids) linker lengths (Figure 21). P1AI5012, P1AJ0690, P1AJ0672, P1AJ0700, and P1AJ0685 contain VHH pair 1. P1AJ0744, P1AJ0735 and P1AJ0747 contain VHH pairs 2.

[0332] FAP-specific IFNγR activation in an integrated format was tested in vitro using the three previously described FAP expression scenarios.

[0333] Based on MHC-I upregulation, the tested monoclonal variants can be divided into three groups. Specifically, variants capable of inducing high levels of MHC-I include the monoclonal variants of recombinant IFNγ, the reference molecule (P1AI5012), and P1AJ0690. Variants capable of inducing moderate MHC-I upregulation include the monoclonal variants P1AJ0672, P1AJ0685, P1AJ0744, and P1AJ0735. Finally, variants capable of inducing low / no MHC-I upregulation belong to this group: P1AJ0700 and P1AJ0747 (Figure 22).

[0334] 3.5 PD-1-dependent bicomponent site assembly using IL-2 mimics in single-molecule format

[0335] To determine whether a single molecule could be achieved that preserves all the features of the splitting IL-2 mimic approach, we designed a four-specificity format that combines the requirements of splitting dual-targeting molecules (Figure 23). The integrated format provides the bicomponent assembly of the cytokine mimic VHH pair by merging two functionally splitting bicomponent molecules into one. First, the most potent splitting conformation of the IL-2 mimic, exhibiting the ability to induce PD1-mediated cis-activity (P1AI1593 and P1AH6814), was selected. Next, the two selected VHH-Fab fusions were grafted onto the single molecule, utilizing the Fc region as a spacer to distance the VHH domain in a PD1-independent manner and reduce the likelihood of VHH-mediated IL-2R activation. Finally, a mortar and cross-Fab technique was combined to generate the four-specificity format while retaining the optimal fusion conformation defined in the P1AI1593 + P1AH6814 combination. In detail, a 5(G4S) joint is used to fuse the IL-2Rβ-specific VHH domain with the N-terminus of the anti-PD1 binder 1 VL domain. The N-terminus of the anti-PD1 binder 1 VH domain is fused to the C-terminus of the Fc pestle chain via a 2(G4S) joint, and the CH1 / CL domain is modified to include additional attracting charges. The anti-PD1 binder 2 is located upstream of the hinge on the mortar chain and contains crossed VH / VL domains. A 5(G4S) joint is used to fuse the IL-2Rγ-specific VHH domain with the N-terminus of the VH domain now located on the light chain.

[0336] To measure the ability of PD-1-targeting IL-2R agonists to induce IL-2R signaling, HEK blue IL-2 cells (Invivogen) with or without human PD-1 expression were used. A reporter system measured secreted SEAP levels as a proxy for STAT-5 phosphorylation via absorbance readings. Briefly, 12,000 cells per well were seeded in 384-well flat-bottomed tissue culture-treated plates (Corning, catalog 3701). The test compound (4-fold dilution series, starting at 100 nM) was added to the assay plates. Samples were incubated at 37°C and 5% CO2 for 20 h according to the manufacturer's instructions, followed by assay readings using QUANTI blue solution (Invivogen, catalog rep-qbs3). Absorbance readings were performed using a Tecan Spark 10M plate reader. The dose-response relationship of the test compound to IL2R signaling (SEAP levels at A650) was plotted in GraphPad Prism software. Although Fc-fused IL-2R agonists exhibit activity in the presence and absence of PD-1, the ability of the monolithic PD-1-targeting IL-2R agonist (P1AI5057) is strongly PD-1 dependent (Figure 24).

[0337] 3.6. Functional characterization of mono- and dual-complementary cis-targeting IL-2R integrated agonists

[0338] To understand the requirements for bi-complementary assembly of IL-2R agonists, we tested the concept of mono-complementary IL-2R signaling by binding to the same PD-1 epitope (Fig. 25). IL-2 signaling was assessed using HEK blue IL-2 wt and HEK blue IL-2 human PD-1 cells. As previously described, bi-complementary assembly of the PD-1-targeting IL-2R agonist (P1AI5057) showed strong dose-responsive IL-2R signaling in reporter assays (Fig. 26B), while no preferred PD-1-dependent activity was observed in the two mono-complementary compounds tested (Figs. 26A and 26B), highlighting the requirement for bi-complementary assembly of functional IL-2R signaling. Notably, the residual PD-1-independent activity of the PD-1-targeting IL-2R agonist was similar to that of both mono-complementary and bi-complementary molecules (Fig. 26A).

[0339] In vitro data provide strong evidence that IFNγ and IL-2 mimics can be engineered for conditional activity under desired settings using a dual complementary site molecular assembly strategy. As a first approach, it has been demonstrated that VHH pairs mimicking IFNγ and IL-2 can become nonfunctional by being distributed across two separate molecules, and that the assembly of functional IFNγ and IL-2 mimics can be mediated under desired conditions. As an extension of this approach, the possibility of designing monomolecular formats that retain both conditional cis and trans activities has been explored. An integrated format is achieved by maintaining the distance between the VHH pairs to inactivate the cytokine mimics while simultaneously adhering to the molecular conformation to meet the geometric requirements for conditional cis and trans agonistic activity. It has been shown that the activity of conditional cytokine mimics can be fine-tuned using both format and geometry.

[0340] sequence

[0341]

Claims

1. An antigen-binding molecule comprising i) First target-binding structural domain ii) Second target-binding structural domain, iii) First cytokine receptor binding domain, iv) Second cytokine receptor binding domain, and v) Fc structural domain, The first target-binding domain can bind to a first epitope on the target antigen, and the second target-binding domain can bind to a second epitope on the target antigen, wherein the first target-binding domain and the second target-binding domain do not compete for binding to the tumor-associated antigen; and The first cytokine receptor binding domain can bind to the first cytokine receptor subunit, and the second cytokine receptor binding domain can bind to the second cytokine receptor subunit.

2. The antigen-binding molecule according to claim 1, wherein the first target-binding domain and the second target-binding domain are antibody fragments, particularly Fv, Fab, scFv, scFab, or single-domain antibodies.

3. The antigen-binding molecule according to any one of the preceding claims, wherein the first target-binding domain and the second target-binding domain are Fab molecules.

4. The antigen-binding molecule according to any one of the preceding claims, wherein the first target-binding domain comprises a heavy chain variable domain (VH1), a light chain variable domain (VL1), a heavy chain constant domain (CH11), and a light chain constant domain (CL1), and the second target-binding domain comprises a heavy chain variable domain (VH2), a light chain variable domain (VL2), a heavy chain constant domain (CH12), and a light chain constant domain (CL2).

5. The antigen-binding molecule according to any one of the preceding claims, wherein the first target-binding domain and / or the second target-binding domain are cross-Fab molecules.

6. The antigen-binding molecule according to any one of the preceding claims, wherein the first target-binding domain and / or the second target-binding domain comprises a charge mutation.

7. The antigen-binding molecule according to any one of the preceding claims, wherein the first target-binding domain is a cross-Fab and the second target-binding domain contains a charge mutation, or wherein the second target-binding domain is a cross-Fab and the first target-binding domain contains a charge mutation.

8. The antigen-binding molecule according to any one of the preceding claims, wherein the first target-binding domain and the second target-binding domain specifically bind to tumor-associated antigens or T-cell antigens.

9. The antigen-binding molecule according to any one of the preceding claims, wherein the first target-binding domain and the second target-binding domain specifically bind to FAP, PD-1, Her2, Her3, LAG-3, CEA, or EGFR.

10. The antigen-binding molecule according to any one of the preceding claims, wherein a) The first target-binding domain comprises VH1 of SEQ ID NO: 20 and VL1 of SEQ ID NO: 21, and the second target-binding domain comprises VH2 of SEQ ID NO: 22 and VL2 of SEQ ID NO: 23, or b) The first target-binding domain comprises VH1 of SEQ ID NO: 22 and VL1 of SEQ ID NO: 23, and the second target-binding domain comprises VH2 of SEQ ID NO: 20 and VL2 of SEQ ID NO: 21, or c) The first target-binding domain comprises VH1 of SEQ ID NO: 80 and VL1 of SEQ ID NO: 81, and the second target-binding domain comprises VH2 of SEQ ID NO: 82 and VL2 of SEQ ID NO: 83, or d) The first target-binding domain comprises VH1 of SEQ ID NO: 82 and VL1 of SEQ ID NO: 83, and the second target-binding domain comprises VH2 of SEQ ID NO: 80 and VL2 of SEQ ID NO: 81; or e) The first target-binding domain comprises VH1 of SEQ ID NO: 82 and VL1 of SEQ ID NO: 83, and the second target-binding domain comprises VH2 of SEQ ID NO: 140 and VL2 of SEQ ID NO: 141; or f) The first target-binding domain includes VH1 of SEQ ID NO: 140 and VL1 of SEQ ID NO: 141, and the second target-binding domain includes VH2 of SEQ ID NO: 82 and VL2 of SEQ ID NO:

83.

11. The antigen-binding molecule according to any one of the preceding claims, wherein the first cytokine receptor subunit and the second cytokine receptor subunit are both subunits of the IFNγ receptor complex or the IL-2 receptor complex.

12. The antigen-binding molecule according to any one of the preceding claims, wherein a) The first cytokine receptor binding domain can bind IFNγR1 and the second cytokine receptor binding domain can bind IFNγR2, or b) The first cytokine receptor binding domain can bind IFNγR2 and the second cytokine receptor binding domain can bind IFNγR1; c) The first cytokine receptor binding domain can bind IL-2Rβ and the second cytokine receptor binding domain can bind IL-2Rγ; or d) The first cytokine receptor binding domain can bind IL-2Rγ and the second cytokine receptor binding domain can bind IL-2Rβ.

13. The antigen-binding molecule according to any one of the preceding claims, wherein the first cytokine receptor binding domain and the second cytokine receptor binding domain are antibody fragments, particularly Fv, Fab, scFv, scFab, single-domain antibodies, or VHH domains.

14. The antigen-binding molecule according to any one of the preceding claims, wherein the first cytokine receptor binding domain and the second cytokine receptor binding domain are VHH domains.

15. The antigen-binding molecule according to any one of the preceding claims, wherein a) The first cytokine receptor binding domain comprises an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 5, and the second cytokine receptor binding domain comprises an amino acid sequence selected from SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 9, or b) The first cytokine receptor binding domain comprises an amino acid sequence selected from SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 9, and the second cytokine receptor binding domain comprises an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 5; or c) The first cytokine receptor binding domain comprises the sequences of SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, and SEQ ID NO: 64, and the second cytokine receptor binding domain comprises the sequences of SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or d) The first cytokine receptor binding domain comprises the sequences of SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68 and SEQ ID NO: 69, and the second cytokine receptor binding domain comprises the sequences of SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62 and SEQ ID NO:

64.

16. The antigen-binding molecule according to any one of the preceding claims, wherein the Fc domain comprises a first Fc domain subunit and a second Fc domain subunit.

17. The antigen-binding molecule according to any one of the preceding claims, wherein the Fc domain is an IgG Fc domain, particularly an IgG1 Fc domain.

18. The antigen-binding molecule according to any one of the preceding claims, wherein the Fc domain is a human Fc domain.

19. The antigen-binding molecule according to any one of the preceding claims, wherein the Fc domain comprises modifications that promote association between a first subunit and a second subunit of the Fc domain.

20. The antigen-binding molecule according to any one of the preceding claims, wherein the Fc domain comprises one or more amino acid substitutions that reduce binding to the Fc receptor and / or effector function.

21. The antigen-binding molecule according to any one of the preceding claims, wherein The first cytokine receptor binding domain fuses at its C-terminus to the N-terminus of the first target binding domain VH1 or VL1, and the first target binding domain fuses at the N-terminus of the first Fc domain subunit to the C-terminus of the first VH1 or VL1. The second cytokine receptor binding domain fuses at its C-terminus to the N-terminus of the second target binding domain VH2 or VL2, and the second target binding domain fuses at the C-terminus of the second Fc domain subunit to the N-terminus of the second CH12 or CL1.

22. The antigen-binding molecule according to any one of the preceding claims, comprising: a) A first polypeptide comprising, in sequence from N-terminus to C-terminus, a first Fc domain subunit, VH1, and CH11; a second polypeptide comprising, in sequence from N-terminus to C-terminus, a first cytokine receptor-binding domain, VL1, and CL1; a third polypeptide comprising, in sequence from N-terminus to C-terminus, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from N-terminus to C-terminus, a second cytokine receptor-binding domain, VH2, and CL2; or b) A first polypeptide comprising, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VL1, and CH11; a second polypeptide comprising, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VH1, and CL1; a third polypeptide comprising, in sequence from the N-terminus to the C-terminus, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VL2, and CL2; or c) A first polypeptide comprising, in sequence from N-terminus to C-terminus, a first Fc domain subunit, VL1, and CL1; a second polypeptide comprising, in sequence from N-terminus to C-terminus, a first cytokine receptor-binding domain, VH1, and CH11; a third polypeptide comprising, in sequence from N-terminus to C-terminus, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from N-terminus to C-terminus, a second cytokine receptor-binding domain, VH2, and CL2; or d) A first polypeptide comprising, in sequence from N-terminus to C-terminus, a first Fc domain subunit, VH1, and CL1; a second polypeptide comprising, in sequence from N-terminus to C-terminus, a first cytokine receptor-binding domain, VL1, and CH11; a third polypeptide comprising, in sequence from N-terminus to C-terminus, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from N-terminus to C-terminus, a second cytokine receptor-binding domain, VL2, and CL2; or e) A first polypeptide comprising, in sequence from the N-terminus to the C-terminus, a first Fc domain subunit, VH1, and CH11; a second polypeptide comprising, in sequence from the N-terminus to the C-terminus, a first cytokine receptor-binding domain, VL1, and CL1; a third polypeptide comprising, in sequence from the N-terminus to the C-terminus, a second cytokine receptor-binding domain, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from the N-terminus to the C-terminus, VH2 and CL2; or f) A first polypeptide comprising, in sequence from N-terminus to C-terminus, a first Fc domain subunit, VL1, and CH11; a second polypeptide comprising, in sequence from N-terminus to C-terminus, a first cytokine receptor-binding domain, VH1, and CL1; a third polypeptide comprising, in sequence from N-terminus to C-terminus, a second cytokine receptor-binding domain, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from N-terminus to C-terminus, VL2 and CL2; or g) A first polypeptide comprising, in sequence from N-terminus to C-terminus, a first Fc domain subunit, VL1, and CL1; a second polypeptide comprising, in sequence from N-terminus to C-terminus, a first cytokine receptor-binding domain, VH1, and CH11; a third polypeptide comprising, in sequence from N-terminus to C-terminus, a second cytokine receptor-binding domain, VL2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in sequence from N-terminus to C-terminus, VH2 and CL2; or h) A first polypeptide comprising, in order from N-terminus to C-terminus, a first Fc domain subunit, VH1, and CL1; a second polypeptide comprising, in order from N-terminus to C-terminus, a first cytokine receptor binding domain, VL1, and CH11; a third polypeptide comprising, in order from N-terminus to C-terminus, a second cytokine receptor binding domain, VH2, CH12, and a second Fc domain subunit; and a fourth polypeptide comprising, in order from N-terminus to C-terminus, VL2 and CL2. VH1, VL1, CH11, and CL1 form the first target-binding domain, and VH2, VL2, CH12, and CL2 form the second target-binding domain.

23. The antigen-binding molecule according to any one of the preceding claims, wherein the first target-binding domain and the second target-binding domain specifically bind FAP, and the first cytokine receptor subunit and the second cytokine receptor subunit are subunits of the IFNγ receptor complex.

24. The antigen-binding molecule according to any one of the preceding claims, comprising: a) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 50; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 48; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 51; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 49; or b) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 99; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 97; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 100; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 98; or c) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 103; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 101; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 104; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 102; or d) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 107; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 105; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 108; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 106; or e) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 99; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 109; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 100; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 110; or f) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 107; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 111; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 113; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 112; or g) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 99; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 114; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 100; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 115; or h) A first polypeptide comprising the amino acid sequence of SEQ ID NO: 107; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 116; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 108; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO:

117.

25. The antigen-binding molecule according to any one of claims 1 to 22, wherein the first target-binding domain and the second target-binding domain specifically bind PD-1, and the first cytokine receptor subunit and the second cytokine receptor subunit are subunits of the IL-2 receptor complex.

26. The antigen-binding molecule according to any one of claims 1 to 22 or 25, comprising a first polypeptide comprising the amino acid sequence of SEQ ID NO: 123; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 122; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 124; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 125.

Citation Information

Patent Citations

  • Methods for producing polypeptides by regulating polypeptide association

    EP1870459A1

  • Chimeric antibody with specificity to human B cell surface antigen

    US5500362A

  • Method for making heteromultimeric polypeptides

    US5731168A

  • Immunoglobulin variants

    US5821337A

  • Electric headlight-lamp

    US617621A

Cited By

  • Bispecific antibody molecule design and optimization method based on computational simulation assistance

    CN121148519A